What are the main reasons MAOIs are underutilized in psychiatric practice despite their proven efficacy for certain conditions? What are the key dietary restrictions patients must follow when taking MAOIs? What are the critical drug-drug interactions clinicians must be aware of when prescribing MAOIs? What clinical pearls or tips would you give to clinicians looking to become more comfortable using these agents?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.  Today, Dr. Andy Cutler interviews Dr. Thomas Schwartz and Dr. Stephen Stahl about factors that have led to the underutilization of MAOIs in psychiatry.  Let’s listen to Part 2 of our theme: Underutilized Psychiatric Drugs.  Subscribe to the NEI Podcast, so that you don’t miss another episode!  Resources  Email [email protected] for guidance on prescribing MAO inhibitors  The Prescriber's Guide to Classic MAO Inhibitors (Phenelzine, Tranylcypromine, Isocarboxazid) for Treatment-Resistant Depression  Practical Guide for Prescribing MAOIs: Debunking Myths and Removing Barriers 

What are the current smoking rates among LGBTQIA+ individuals compared to the general population? What unique barriers do LGBTQIA+ individuals face when trying to quit smoking? What are the recommended pharmacotherapies and behavioral interventions for smoking cessation? What training is needed for providers to deliver culturally affirmative smoking cessation treatment for LGBTQIA+ patients?  Dr. Rhonda Schwindt is an Associate Professor at The George Washington University School of Nursing. She is a nationally certified Psychiatric-Mental Health Nurse Practitioner with an active clinical practice specializing in LGBTQIA+ health, trauma, and treatment-resistant mood disorders. Dr. Schwindt earned a Doctor of Nursing Practice degree from Case Western Reserve University, a Master of Science in Nursing from Indiana University School of Nursing, a Bachelor of Arts from Purdue University, and a diploma in nursing from St. Elizabeth School of Nursing. Dr. Schwindt has a funded program of research focused on improving health outcomes for the LGBTQIA+ community. She led a team of researchers that examined barriers to, and facilitators of, smoking cessation and treatment utilization in the transgender and gender expansive population as well as studies exploring best practices for teaching graduate students how to provide affirming care. Dr. Schwindt has received international recognition as an outstanding graduate nurse educator and for clinical excellence in the care of persons living with serious mental illness.  Resources  Pride in Being Tobacco-Free  UCSF Smoking Cessation Leadership Center  Fenway Health  Trevor Project 

In this CME episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo about the current landscape of tardive dyskinesia, including screening, diagnosis, and treatment. Practical strategies based on the latest data are reviewed at length, particularly for long-term management of tardive dyskinesia.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Consider the individual patient profile and symptoms when determining a treatment plan for patients with tardive dyskinesia Integrate latest safety, efficacy, and tolerability data of VMAT2 inhibitors into decision-making processes when considering treatment options for tardive dyskinesia Evaluate practical strategies for patient follow-up and long-term VMAT2 inhibitor treatment Evaluate and integrate recent updates and advancements regarding evidence-based treatment strategies for tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour Released: June 26, 2024*   Expiration: June 25, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-02-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until June 25, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.0 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Laxman B. Bahroo, DO, MS, FAAN Professor and Residency Program Director, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC Consultant/Advisor: AbbVie, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Revance, Supernus Speakers Bureau: AbbVie, Acadia, Acorda, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Supernus, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O’Brien, Meghan Grady, Brielle Calleo, and Andrea Zimmerman, EdD. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email [email protected]. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

What are the properties of lithium that make it a unique treatment option? What are the main reasons why lithium is underutilized in clinical practice, and what are the consequences of underutilization? What are the common myths or misconceptions about lithium’s safety and tolerability? How can we better educate patients about the benefits of lithium and address concerns about side effects or monitoring requirements that may impact adherence?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.  Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of lithium in psychiatry.  Let’s listen to Part 1 of our theme: Underutilized Psychiatric Drugs.  Subscribe to the NEI Podcast, so that you don’t miss another episode!    Resource  The Lithium Handbook 

Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Recognize the significance of comprehensive measures that assess both healthcare practitioner-perceived severity of tardive dyskinesia symptoms and the patient-reported impact of tardive dyskinesia on daily life Engage in informed discussions with patients about the rationale behind incorporating additional medications to manage side effects arising from primary antipsychotic medication Consider all facets of patient health, including physical, mental, and social well-being, when formulating strategies for managing tardive dyskinesia symptoms Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour. Released: June 05, 2024*   Expiration: June 04, 2027 *NEI maintains a record of participation for six (6) years. Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.00 ANCC contact hours Nurse Practitioner: ACCME?AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour(s) of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour(s) (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit(s). Approval is valid until June 04, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Desiree M. Matthews, MSN, PMHNP-BC Founder and Clinical Director, Different MHP, PC, Charlotte, NC Consultant/Advisor: Alkermes, Biogen, Boehringer Ingelheim, Karuna, Indivior, Janssen Pharmaceuticals, Neurocrine Biosciences, Sage Therapeutics, Takeda, Teva Speakers Bureau: AbbVie, Axsome, Neurocrine Biosciences, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O’Brien and Meghan Grady. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email [email protected]. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

How do symptoms of agitation manifest differently in disorders such as bipolar disorder, schizophrenia, and dementia, and what challenges does this pose for assessment? What are the most effective pharmacological treatments for acute agitation in psychiatric patients, and how do you determine the best course of action? How do cultural factors influence the approach to managing agitation in various mental health conditions? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Leslie Citrome and Dr. Stephen Stahl about the clinical difficulties of treating agitation.  Let’s listen to Part 3 of our theme: Untreatable Dimensions of Psychopathology.  Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are the hypothesized neurobiological mechanisms that support the use of cannabidiol (CBD) as a treatment for opioid use disorder (OUD)? How does CBD influence cue-induced craving in OUD? What are the challenges and opportunities in further exploring the use of CBD as a potential treatment for OUD? Dr. Joji Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women’s Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School. His areas of clinical and research interests are the assessment and management of substance use disorders and related conditions in general medical settings, motivational interviewing, office-based opioid treatment, implementation of collaborative models of care, and medical education. He is the site director for the Partners Addiction Psychiatry Fellowship, and is involved with teaching medical students, residents, and allied health professionals. He has authored over 30 peer-reviewed manuscripts and book chapters related to addiction psychiatry.

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation, Setting the Mood: Strategies for Diagnosing and Treating ADHD in the Context of Bipolar Disorder, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Manpreet Singh addresses your unanswered questions from her joint presentation, Don’t Get Mixed Up! Recognizing and Treating Mixed Features Across the Lifespan, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Dani Cabral addresses your unanswered questions from her presentation, Memories in the Future: An Update on the Diagnosis and Treatment of Alzheimer’s Disease, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Sarah Vinson addresses your unanswered questions from her panel presentation, Serious Mental Illness: A Collaborative Approach, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

How does dysfunction in cognition affect overall treatment outcomes for psychiatric disorders? What are the challenges in treating cognitive deficits in psychiatric conditions? What treatments are in development for cognitive dysfunction? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Richard Keefe and Dr. Stephen Stahl about the clinical difficulties of treating cognitive dysfunction.  Let’s listen to Part 2 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don’t miss another episode! ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are some common challenges faced by caregivers of individuals with dementia? What is comprehensive dementia care and how does it improve quality of life of individuals with dementia and their caregivers? What is the GUIDE Model and why is it needed?  Carolyn Clevenger, DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA is a Professor at the Nell Hodgson Woodruff School of Nursing at Emory University. Dr. Clevenger is a nationally recognized educational leader in advanced practice nursing and in geriatrics and gerontology. She is a Past President of the Gerontological Advanced Practice Nurses Association, Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America, and contributor to the AANP Certification Program. She is the director of the nurse-led patient centered medical home for people living with dementia, the Integrated Memory Care Clinic (IMCC). IMCC represents an innovative clinical model that provides memory and primary care in a single integrated model for people living with dementia and their care partners.  Resources Alzheimer’s Association KAER toolkit ROON   ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What is the role of mindfulness techniques in the treatment of anxiety disorders and how is it evolving? How does mindfulness-based stress reduction compare to pharmacological treatment for anxiety disorders? What are the hypotheses that have been made about why mindfulness-based treatments work for anxiety? Elizabeth Hoge, MD is a Professor and Director of the Anxiety Disorders Research Program in the Department of Psychiatry at Georgetown University School of Medicine. Dr. Hoge completed her psychiatry residency training and research fellowship at the Massachusetts General Hospital in Boston. During her research fellowship, she earned a Masters in Medical Science from the Harvard Medical School-Massachusetts Institute of Technology program in Health Sciences and Technology with a focus on clinical trials. Her research focuses on treatments for anxiety disorders, including medication, psychotherapy and mindfulness, and the examination of biomarkers of anxiety, stress, and trauma. She has over 50 publications in the medical research literature and is on the Scientific Council of the Anxiety and Depression Association of America. ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are the cultural factors that should be considered when providing mental health care to migrant and refugee populations? What challenges and opportunities exist in providing mental health care to these communities? How can mental health professionals collaborate with other disciplines to create a holistic approach to address the mental health needs of migrant and refugee populations?  Lisa Fortuna, MD, MPH is the Chief of Psychiatry and Neurosciences at the Riverside School of Medicine. She was the Chief of Psychiatry and Vice-Chair at Zuckerberg San Francisco General Hospital/UCSF and Associate Professor of Clinical Psychiatry. She has been an investigator on several National Institutes of Health and foundation-funded studies of Latino and immigrant mental health, integrated care, access to care including a principle investigator of a NIMH funded R01 aimed at optimizing family navigation for addressing child behavioral health in primary care and a Patient Centered Outcome Research Institute (PCORI) funded multi-site large pragmatic trial on the treatment of childhood anxiety comparing face to face vs. digitally delivered CBT in English and Spanish called Kids FACE FEARS. Her areas of expertise are child and adolescent psychiatry, treatment and research on PTSD across the lifespan, immigrant mental health and disparities/ access to care including digital interventions research. 

How does anhedonia impact the overall treatment plan for patients with major depressive disorder and other psychiatric conditions? What are some of the most challenging aspects of treating anhedonia in patients? Are there any new treatments in development that may be helpful for treating anhedonia? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Vladmir Maletic and Dr. Stephen Stahl about the clinical difficulties of treating anhedonia  Let’s listen to Part 1 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don’t miss another episode!

During Black History Month, we revisit an enlightening conversation with Dr. Sarah Vinson about the impact of structural racism on Black mental health and how mental healthcare providers can make a difference in the lives of patients by leveraging their privilege and skillsets.  Dr. Sarah Y. Vinson is a physician who is triple-board certified in adult, child & adolescent, and forensic psychiatry. She is the founder of the Lorio Psych Group, an Atlanta, GA based mental health practice providing expert care and consultation. Dr. Vinson is also the founder of Lorio Forensics, which provide consultation on a wide variety of cases in criminal, civil, and family court cases. After graduating from medical school at the University of Florida with Research Honors and as an Inductee in the Chapman Humanism Honors Society, she completed her general psychiatry training at Cambridge Health Alliance/Harvard Medical School. While there, she also received specialized training in trauma through the Victims of Violence Program. She then returned to the South to complete fellowships in both child & adolescent and forensic psychiatry at Emory University School of Medicine. In addition to providing mental health care services such as psychotherapy, consultation, and psychopharmacology through her private practice, Dr. Vinson is a Professor and Chair of the Department of Psychiatry & Behavioral Sciences at Morehouse School of Medicine. She is also Adjunct Faculty at Emory University School of Medicine. She is the Past President of the Georgia Council on Child and Adolescent Psychiatry, and the Treasurer of the Georgia Psychiatric Physicians Association. Additionally, she is an Advisor for the Judges Psychiatry Leadership Initiative. Dr. Vinson has been a speaker at national conferences including the American Psychiatric Association Annual Meeting, the American Academy of Child and Adolescent Psychiatry Annual Meeting and The National Urban League Annual Meeting. Dr. Vinson has received numerous awards in recognition of her service and leadership including the University of Florida College of Medicine Outstanding Young Alumna Award and the APA Jeanne Spurlock Minority Fellowship Alumna Achievement Award.    Resources  Social (In)justice in Mental Health  Judges and Psychiatrists Leadership Initiative  Ourselves Black 

Can the therapeutic benefits of psilocybin be achieved without a psychedelic trip? What is the role of psychological support in the therapeutic effect of psilocybin? What is microdosing and what are its potential benefits and risks? What is the path to FDA approval and commercialization of psilocybin and other psychedelics?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry.  Today, Dr. Andy Cutler interviews Dr. Charles Raison and Dr. Stephen Stahl about the importance of the psychedelic trip for the therapeutic benefits of psilocybin.  Let’s listen to Part 4 of our theme: Classic Psychedelics for the Modern Psychopharmacologist.  Subscribe to the NEI Podcast, so that you don’t miss another episode! 

The climate crisis has a wide-reaching impact that negatively affects both acute and long-lasting mental health outcomes. Are there specific populations that are more vulnerable to mental health issues related to the climate crisis? What is the role of mental health professional to combat the negative influence of climate change on mental health? Robin Cooper, MD, is a psychiatrist who has had a private practice in San Francisco for 40 years, is Associate Clinical Professor in the Department of Psychiatry and Behavioral Sciences at the UCSF Medical School, where she is actively involved in efforts to address climate change impacts on mental health and health. She is co-founder of Climate Psychiatry Alliance, a national group of psychiatrists and mental health professionals dedicated to understanding, educating, and advocating about the specific impact of climate change on mental health. As she moves into semi-retirement in her clinical work, her work around climate change impacts on health and mental health have become a second career.

In this CME episode, Dr. Andrew Cutler interviews Dr. Dani Cabral about current and novel diagnostic tools and treatments for Alzheimer’s disease. Optional CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the potential role of multimodal imaging and biomarker strategies in the diagnostic process for Alzheimer’s disease Assess the safety and efficacy of novel disease-modifying pharmacological treatments for Alzheimer’s disease Describe potential future advancements in the diagnosis and treatment of Alzheimer’s disease Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Dani Cabral, MD Assistant Clinical Professor, Departments of Neurology and of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ Dementia Specialist, Banner Sun Health Research Institute, Sun City, AZ Consultant/Advisor: Eisai, Lilly, Roche/Genentech Interview Questions Author Caroline L. O’Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewers have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Eisai. Released: December 27, 2023      CE credit expires: December 27, 2026

What do the clinical trials of psilocybin and other psychedelics show in terms of efficacy and safety? How much of the benefit with psychedelic treatment is attributable to psychological support? Is the psychedelic trip important for the therapeutic benefits of psychedelic treatments? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry. Today, Dr. Andy Cutler interviews Dr. Scott Aaronson and Dr. Stephen Stahl about the potential indications and therapeutic benefits of psilocybin and other psychedelics. Let’s listen to Part 3 of our theme: Classic Psychedelics for the Modern Psychopharmacologist. Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-GEN Learning Objectives: After completing this educational activity, you should be better able to: Recognize the role of a patient’s genetics in informing the efficacy and tolerability of antidepressants Consider opportunities to use pharmacogenomics as an evidence-based tool that can be employed to inform clinical decision making Implement pharmacogenomic testing to optimize patient outcomes, including symptom improvement, medication response, and remission rate Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Jeffrey R. Strawn, MD Professor, Department of Psychiatry and Behavioral Neuroscience and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH Grant/Research: Allergan/AbbVie Consultant/Advisor: Cerevel, Intra-Cellular, Otsuka Pre-Interview Author Gabriela Alarcón, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Myriad Genetics. Released: December 13, 2023      CME/CE credit expires: December 13, 2026

What were some new treatments approved by the FDA? What did we learn about the long-term safety of methylphenidate in childhood ADHD? Are there benefits to long-term maintenance treatment with antidepressants in bipolar disorder? What did we learn about the safety and efficacy of subcutaneous racemic ketamine for treatment-resistant depression and MDMA for PTSD? In this episode, Dr. Andrew Cutler and Dr. Roger McIntyre address these questions and so much more about this past year in psychopharmacology.   Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His work broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.    

In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the burden of residual symptoms in patients with major depressive disorder (MDD) Implement measurement-based care to assess residual MDD symptoms Modify treatment strategies to address residual MDD symptoms, including cognitive impairment, anhedonia, emotional blunting, and sexual dysfunction Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Vladimir Maletic, MD, MS Clinical Professor, Department of Psychiatry and Behavioral Science, University of South Carolina School of Medicine Greenville, SC Consultant/ Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Biogen/Sage, Boehringer Ingelheim, Cervel, Intra-Cellular, Janssen, Jazz, Lundbeck, Neurelis, Neumora, Noven, Otsuka, Pax Medica, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Axsome, Corium, Intracellular, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda Pre-Interview Author Caroline L. O’Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Takeda. Released: November 29, 2023      CME/CE credit expires: November 29, 2026

In this episode, Dr. Vladimir Maletic addresses your unanswered questions from his presentations, “From Despair to Delight: Advances in the Diagnosis and Treatment of Anhedonia” and “Ho Hum to Aha! Treating Anhedonia and Emotional Blunting.”

In this episode, Dr. Leslie Citrome addresses your unanswered questions from his presentation, There’s No Place Like Home: Addressing Agitation in Dementia.

What is the role of the 5HT2A receptor in the therapeutic actions of psychedelics? What additional mechanisms may be involved in the therapeutic benefits of classic psychedelics? Is the psychedelic trip necessary for the therapeutic benefit of psychedelics?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry.  Today, Dr. Andy Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl about the current understanding of the neurobiological mechanisms underlying the therapeutic benefits of psychedelics.  Let’s listen to Part 2 of our theme: Classic Psychedelics for the Modern Psychopharmacologist.  Subscribe to the NEI Podcast, so that you don’t miss another episode!   

In this episode, Dr. Laxman Bahroo addresses your unanswered questions from his presentation, Neurology for Psychiatrists.

In this episode, Dr. Roger McIntyre addresses your unanswered questions from his presentation, Unveiling the Therapeutic Potential: Evidence Supporting the Use of Psychedelics for PTSD, SUD, and Other Indications, at the Pre-Conference Psychedelics Workshop.

In this episode, Dr. Timothy Wilens addresses your unanswered questions from his presentation, Double Trouble: Diagnosis and Pharmacotherapy of ADHD and Juvenile Bipolar Disorder, at the Child & Adolescent Psychiatry Academy.

In this episode, Dr. Robyn Thom addresses your unanswered questions from her presentation, The Full Picture: Managing Autism Spectrum Disorder and Its Frequent Psychiatric Comorbidities, at the Child & Adolescent Psychiatry Academy.

In this episode, Dr. Jeffrey Strawn addresses your unanswered questions from his presentation, Along for the Ride: Treatment Considerations for Childhood Psychiatric Disorders With Co-Occurring Anxiety, at the Child & Adolescent Psychiatry Academy.

Stigma surrounding mental illness and its treatment can be pervasive and negatively impact the quality of life of patients suffering with mental health problems. What role do psychiatric healthcare providers play in addressing and combating mental illness stigma? How do cultural factors influence the perception of mental illness and stigma? What are the best strategies for reducing stigma related to mental illness? Dawn I. Velligan, PhD is a Professor in the Department of Psychiatry, Chief of the Division of Community Recovery, Research and Training, and the Henry B. Dielmann Chair at the University of Texas Health Science Center in San Antonio, Texas. Dr. Velligan’s internationally recognized research program focuses on the development and testing of psychosocial treatments to improve medication interest, follow-through, and outcomes for people with schizophrenia. She developed cognitive adaptation training; a treatment designed to improve functional outcomes for people with serious mental illness. Dr. Velligan is an author of numerous publications in high impact journals and has received grant funding from the National Institutes of Health, The National Alliance for Research on Schizophrenia and Depression, industry, and private foundations.

The 19th annual NEI Congress is upon us. Whether you’ve already secured your spot to join us in person at The Broadmoor in Colorado Springs or plan to attend virtually via simulcast OR are still unsure if this event is for you, you’re in luck. This is our Congress preview episode. Congress chairman, Dr. Andrew Cutler interviews a few of the brilliant faculty members who will be speaking at this year’s conference for a sneak peek of their presentations and finds out what they are looking forward to at the upcoming event.

What are classic psychedelic drugs and how has their role in psychiatry changed over time? What are the potential benefits of using psychedelic therapy for treating psychiatric disorders? Are there any significant risks and what are the potential side effects associated with psychedelic therapy? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry. Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of psychedelic research in psychiatry.  Let’s listen to Part 1 of our theme: Classic Psychedelics for the Modern Psychopharmacologist. Subscribe to the NEI Podcast, so that you don’t miss another episode!

How large of an issue is treatment non-adherence in the serious mental illness (SMI) population? How does therapeutic alliance influence treatment adherence? What are some effective strategies for improving medication adherence? Dr. Andrew Cutler interviews Dr. Peter Weiden to find answers to these questions and more! Peter J. Weiden, MD is an internationally recognized expert in the treatment of schizophrenia and related psychotic disorders. Dr. Weiden has a distinguished career spanning academia, clinical trials, and industry. His academic career included positions as Professor of Psychiatry at SUNY Downstate Medical Center from 1999-2007 and at UIC Medical Center from 2007-2014. Dr. Weiden served as Chief Medical Officer for Uptown Research in Chicago and continued as clinical investigator of new and emerging treatments for schizophrenia. His industry experience includes joining Alkermes to focus on development of new treatments for schizophrenia, including the long-acting formulation aripiprazole lauroxil and the combination product olanzapine/samidorphan. He joined Karuna Therapeutics in 2020 to support development of the investigational muscarinic agonist xanomeline-trospium, currently in phase 3 development for the treatment of schizophrenia. This year, Dr. Weiden returned to clinical practice and provides consulting and educational services via PJWeiden, LLC. His areas of expertise include drug development, clinical trials, and clinician education.

In this re-release episode, Dr. Andrew Cutler interviews Dr. Katherine Warburton about the history of criminalization of serious mental illness, the efforts to decriminalize mental illness, and the development and success of diversion programs. Dr. Katherine Warburton is Medical Director/Deputy Director of Clinical Operations for the California Department of State Hospitals. Prior to that, she was the Chief of Forensic Psychiatry at Napa State Hospital. She is on the volunteer clinical faculty of the UC Davis Division of Psychiatry and the Law. Link to “Decriminalizing Mental Illness” by Drs. Warburton and Stahl: https://www.amazon.com/Decriminalizing-Mental-Illness-Katherine-Warburton/dp/1108826954/ref=sr_1_1?crid=18XJ6RE7Y5X5M&keywords=warburton+stahl&qid=1657746214&sprefix=warburton+stahl%2Caps%2C112&sr=8-1

During National Recovery Month, we are re-releasing this classic episode in which Dr. Sabrina Segal interviews addiction expert Dr. Nzinga  Harrison about the need to address stigma and misconceptions surrounding the topic of addiction. When it comes to addiction, there are many questions. What does it mean to say that someone is in recovery? What are some behavioral addictions that most people don’t think about? Are there such things as healthy addictions? In this episode, Dr. Harrison shares a refreshing and novel perspective on the topics of addiction and recovery. A well-respected physician and educator, Dr. Harrison is the host of the In Recovery weekly podcast by Lemonada Media, in which she engages a large audience on all things addiction with the goal of leading with compassion, evidence and reducing stigma. She is Chief Medical Officer and Co-Founder of  Eleanor Health, an innovative company that provides comprehensive, longitudinal outpatient care for individuals experiencing opioid and other substance use disorders. She earned her bachelor’s degree in biology with Spanish and Chemistry minors at Howard University, completed medical school at the University of Pennsylvania School of Medicine and General Psychiatry Residency at Emory University. She is Board-Certified in both Adult General Psychiatry and Addiction Medicine and has spent her career treating individuals with Serious Persistent Mental Illness and Addictive Diseases. Currently she holds adjunct faculty appointments at the Morehouse School of Medicine Department of Psychiatry is Co-Founder of Physicians for Criminal Justice Reform, Inc. and Campaign Psychiatrist for Let’s Get Mentally Fit, a public education and stigma-reduction campaign. Resources: Dr. Nzinga Harrison’s In Recovery Podcast: https://www.lemonadamedia.com/show/in-recovery/ Eleanor Health: https://www.eleanorhealth.com

In this re-release episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the dark side of neuroplasticity, or pathologic neuroplasticity, and what we may be able to do to combat it.

What led you to pursue a career in auditory neuroscience and what is the mission behind your laboratory, Brainvolts? What is the effect of bilingualism on Alzheimer’s disease? How can sound be used for the assessment of traumatic brain injury and other neurological conditions? In this episode, Dr. Nina Kraus addresses these questions and much more about the clinical applications for auditory neuroscience research. Her laboratory at Northwestern University, Brainvolts, has discovered how to measure the biology of auditory processing with unprecedented precision. The implications of the research conducted there extends beyond the laboratory to schools, community centers, and clinics. Nina Kraus, Ph.D. is a professor at Northwestern University who studies the biology of auditory learning. Through a series of innovative studies involving thousands of research participants from birth to age 90, her research has found that our lives in sound, for better (musicians, bilinguals) or worse (language disorders, concussion, aging, hearing loss), shape auditory processing. She continues to conduct parallel experiments in animal models to elucidate the mechanisms underlying these phenomena. Never having accepted a lack of technology as a roadblock to scientific discovery, Kraus has invented new ways to measure the biology of sound processing in humans that provide precision and granularity in indexing brain function. With her technological innovations she is now pushing science beyond the traditional laboratory by conducting studies in schools, community centers, and clinics. Using the principles of neuroscience to improve human communication, she advocates for best practices in education, health, and social policy. Dr. Kraus is the author of the book “Of Sound Mind: How our Brain Constructs a Meaningful Sonic World.” Resources: Brainvolts: https://brainvolts.northwestern.edu/about-us/ Learn more about Of Sound Mind: How our Brain Constructs a Meaningful Sonic World: https://www.amazon.com/Sound-Mind-Brain-Constructs-Meaningful/dp/0262045869# BEAMS hypothesis: https://brainvolts.northwestern.edu/wp-content/uploads/2021/07/Kraus_BEAMS_2021-1.pdf

In this CME episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Sarah Vinson about the ethicality and morality of involuntary treatment for serious mental illness (SMI), the relationship between SMI and the criminal justice system, and community-based changes that are being pursued to improve treatment and reduce the criminalization of SMI. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-SMI Learning Objectives: After completing this educational activity, you should be better able to: Recognize the neuroethics involved in involuntary treatment of serious mental illness Identify methods to prevent patients with serious mental illness from entering the criminal justice system, including the utility of diversion programs Institute community-based changes that have the potential to reduce the criminalization of serious mental illness, both on the individual and the policy level Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity does not pertain to pharmacology and is worth 0.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Interprofessional Continuing Education: IPCE credit for learning and change Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewees Stephen M. Stahl, MD, PhD, DSc (Hon.) Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Editor-in-Chief, CNS Spectrums Director of Psychopharmacology Services, California Department of State Hospitals Grant/Research: Acadia, Alkermes, Allergan/AbbVie, Arbor, AssureX, AstraZeneca, Avanir, Axovant, Biogen, Boehringer Ingelheim Braeburn, BristolMyer Squibb, Celgene, CeNeRex, Cephalon, Daiichi Sankyo-Brazil, Dey, Eisai, Forest, Genomind, Glaxo Smith Kline, Harmony Biosciences, Indivior, Intra-Cellular, Ironshore, Janssen, JayMac, Jazz, Lilly, Lundbeck, Merck, Neurocrine, Neuronetics, Novartis, Otsuka, Pear, Pfizer, Reviva, Roche, Sage, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Teva, Tonix, Torrent, Vanda Consultant/Advisor: Acadia, Adamas, Alkermes, Allergan/AbbVie, Altus, Arbor, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Cerevel, ClearView, Clexio, Concert, DepotMed, Done, EMD Serono, Eisai, Enveric, Eurolink, Fabre-Kramer, Ferring, Forest, Gedeon Richter, Genetica, Genomind, Innovative Science Solutions, Impel, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Libbs, Lilly, Lipidio, Longboard, Lundbeck, Merck, Neos, NeuraWell, Neurocrine, NeuroPharma, Novartis, Noveida, Otsuka, Perrigo, Pfizer, Pierre Fabre, Proxymm, Recordati, Relmada, Reviva, Sage, Saniona, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Taliaz, Teva, Tonix, Tris, Trius, Vanda, Vertex, Viforpharma Speakers Bureau: Acadia, Allergan/AbbVie, Genentech, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Servier, Sunovion, Takeda, Teva Options Holdings: Delix, Genomind, Lipidio, NeuraWell Sarah Y. Vinson, MD, FAPA Interim Department Chair; Clinical Associate Professor; Director, Child and Adolescent Psychiatry Fellowship Program; Department of Psychiatry and Behavioral Sciences, Morehouse School of Medicine, Atlanta, GA Medical Director, Substance Abuse and Mental Health Services Administration (SAMHSA) African American Behavioral Health Center of Excellence, Atlanta, GA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Alkermes. Released: July 25, 2023      CME/CE credit expires: July 24, 2026

In this re-release episode, Dr. Andrew Cutler interviews Drs. Marko Perko and Stephen Stahl about their book, Tesla: His Tremendous and Troubled Life, which explores the intersection between Tesla’s genius, his creativity, and his bipolar disorder. Sadly, Dr. Marko Perko passed away last fall after a battle with cancer. He was a prolific writer and a great mind, and we re-release this episode in his honor.   Learn more about Tesla: His Tremendous and Trouble Life

NEI Podcast is taking a temporary hiatus over the summer. From July through September, we will revisit some of our most compelling episodes, on topics that remain as relevant today as when they first aired. New episodes will resume in the fall; make sure you are subscribed so that you don’t miss out!  ***************************** What is unique about collaborative care when it comes to mental health? Can you share some of the step-by-step guide to implementing the core model in clinical practice for collaborative care? In this episode, Dr. Anna Ratzliff answers these questions and much more!   Dr. Anna Ratzliff is a national expert on collaborative care, and specifically on training teams to implement and deliver mental health treatment in primary care settings. Her passion for translating complex research ideas into practical real-world applications began when she received her MD and PhD in Anatomy and Neurobiology as part of the Medical Scientist Training Program at the University of California at Irvine. She currently is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington, where she has developed additional expertise in suicide prevention training, mental health workforce development, adult learning best practices, and mentorship. Dr. Ratzliff is the Director of the UW Psychiatry Resident Training Program, Co-Director of the AIMS Center (Advancing Integrated Mental Health Solutions), and Director of the UW Integrated Care Training Program for residents and fellows.  Resources:   AIMS Center Website: http://aims.uw.edu/  Implementation Guide: https://aims.uw.edu/collaborative-care/implementation-guide  APA Training: https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care 

What are some of the greatest challenges when treating ADHD in the elderly population? Are stimulants safe in the elderly population? How do hormonal changes influence ADD or ADHD in women throughout life?  With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD). Today, Dr. Andy Cutler interviews Dr. David Goodman on treating ADHD across the lifespan. Let’s listen in to Part 3 of our theme: Treating ADHD Across the Lifespan. Subscribe to the NEI Podcast, so that you don’t miss another episode!

What is avoidant/restrictive food intake disorder or ARFID? How does it differ from other disorders? How are intestinal microbiota involved when it comes to eating disorders? Dr. Cynthia Bulik is a Distinguished Professor of Eating Disorders and Founding Director of the University of North Carolina (UNC) Center of Excellence for Eating Disorders and Professor of Nutrition, Gillings School of Global Public Health; and Associate Director, UNC Center for Psychiatric Genomics. Dr. Bulik’s research teams at UNC (Center of Excellence for Eating Disorders-CEED) and Karolinska Institute (Centre for Eating Disorders Innovation-CEDI) are dedicated to deepening our understanding of the underlying biology and genetics of eating disorders and to advancing the evidence base for the treatment of these illnesses. As founder and co-chair of the Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED), she leads the global effort to identify actionable genomic variation in eating disorders. She is Principal Investigator of the global Eating Disorders Genetics Initiative funded by the National Institute of Mental Health. She is also the Principal Investigator of the largest study of genetic and environmental contributors to avoidant/restrictive food intake disorder (ARFID-GEN), also funded by the National Institute of Mental Health. Together with Ian Carroll, PhD she conducts population-level and intensive longitudinal clinical investigations of the intestinal microbiota in eating disorders. For the past decade, with Donald Baucom, PhD and Jennifer Kirby, PhD she has developed and disseminated a suite of couple-based interventions for anorexia nervosa, bulimia nervosa, and binge-eating disorder (UNITE: UNiting couples In the Treatment of Eating disorders). She also serves as senior faculty on the SAMHSA-funded National Center of Excellence for Eating Disorders (NCEED)—the national authoritative source for information and training in eating disorders. She is dedicated to mentorship of junior investigators, especially women in STEM fields and is passionate about translating science for the public.

What has research demonstrated about the advantages and consequences of telehealth for the treatment of ADHD and mental health? How can we fill the gaps in underserved communities when it comes to telehealth treatment for ADHD? With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD). Today, Dr. Andy Cutler interviews Dr. Greg Mattingly on best practices and guidelines for using telemedicine for the treatment and management of ADHD. Let’s listen in to Part 2 of our theme: The Challenges of Treating ADHD Online Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are common comorbidities with ASD and how difficult is it to differentiate these conditions from overlapping symptoms of ASD? What guidelines are there for managing agitation in autism spectrum disorder? Robyn Thom, MD, is a child, adolescent, and adult psychiatrist at the Massachusetts General Hospital (MGH) Lurie Center for Autism and co-Director of the MGH Williams Syndrome Program. She is also an Assistant Professor of Psychiatry at Harvard Medical School. She specializes in diagnosing and treating comorbid psychiatric conditions in individuals with autism spectrum disorder and other developmental disabilities including Williams syndrome. Dr. Thom's research interests include psychopharmacology, anxiety disorders, Williams syndrome, medical comorbidity in adults with autism spectrum disorder, and brain aging.

What is the proposed neurocircuitry that underlies attention deficit hyperactivity disorder, or ADHD? What is known about the role of serotonin in ADHD? Particularly the 5HT2C and 5HT7 receptors? With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on novel perspectives and novel treatment approaches for Attention Deficit Hyperactivity Disorder (ADHD). Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of ADHD and where the future lies. Let’s listen in to Part 1 of our theme: Shifting Focus: A Novel Perspective on Attention Deficit Hyperactivity Disorder (ADHD) Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, Dr. Jonathan Meyer addresses your unanswered questions from his presentation: Dopamine Partial Agonists: How They Work and Why They Don’t Always Play Nice with Other Antipsychotics.

In this episode, Dr. Jade Wu addresses your unanswered questions from her presentation: Goodnight Mom: Sleep Issues During Pregnancy and Postpartum.

In this episode, Dr. Roger McIntyre addresses your unanswered questions from his presentation: The “Mania” Event: Distinguishing Between Treating Bipolar I and Bipolar II.

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation “ADHD: Optimizing Treatment with Patient-Centered Care 

In this episode, Dr. Thomas Schwartz addresses your unanswered questions from his presentation “Can You Say Hey? The Many Faces of Serotonin 5HT2A” by Dr. Thomas Schwartz 

How does precision medicine relate to treating Alzheimer’s disease? Can you share more with us about the blood biomarker research at Johns Hopkins?   With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment.   Today, Dr. Andy Cutler interviews Dr. Kostas Lyketsos about the most current research on treatment for Alzheimer’s disease, including precision medicine and behavioral modifications.   Constantine (Kostas) Lyketsos, MD, MHS, FACLP, FACNP is an active clinician, teacher, and researcher, Dr. Lyketsos was the founding director of the Johns Hopkins Neuropsychiatry Service, which he led for over a decade. He developed one of the largest and most successful academic neuropsychiatry programs in the USA with special expertise in dementia and traumatic brain injury. Prior to taking leadership of the Johns Hopkins Bayview Department of  Psychiatry, he was co-director of the Johns Hopkins Division of Geriatric Psychiatry and Neuropsychiatry. He has held a joint faculty appointment at the Hopkins Bloomberg School of Public Health since 1994.  Let’s listen in to Part 3 of our theme: Alzheimer’s Disease: Beyond the Amyloid Hypothesis: Prevention, Management and Treatment of Alzheimer’s Disease   Subscribe to the NEI Podcast, so that you don’t miss another episode! 

What is Match Day? What types of resources does Inside the Match provide for match applicants? In this episode, psychiatry resident, Dr. Simone Bernstein addresses these questions and much more! Simone Bernstein is a fourth-year psychiatry resident at Washington University in St. Louis and Co-Founder of Inside the Match, a platform that provides free application and interview guidance to residency applicants as well as tips to be successful in residency. The platform has a website with 250+ blogs to help you prepare for the match and more than 120+ episodes on Spotify, Apple, and Google podcasts. Simone has spoken at conferences worldwide, is a Laughlin Fellow, Forbes 30 Under 30 Social Entrepreneur, was featured as one of Glamour Magazine’s Top 10 College Women, is an inductee in the Missouri Public Affairs Hall of Fame, and is also a Fulbright Scholar. Find Inside The Match on Instagram and Twitter @Inside_TheMatch. 

What sorts of imaging techniques are used to measure amyloid aggregates in the brain? What do we know about the relationship between symptoms of Alzheimer’s disease and amyloid levels that are detected through neuroimaging? With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment. Today, Dr. Andy Cutler interviews Dr. Lon Schneider on biomarkers for Alzheimer’s disease and treatments that target amyloid. Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health). In addition, he is principal investigator of the National Institute of Mental Health's CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer's disease. Let’s listen in to Part 2 of our theme: Biomarkers and Treatments that Target Amyloid Subscribe to the NEI Podcast, so that you don’t miss another episode!

What cultural perspectives may influence mental health stigma in the Middle East? What was your experience like creating the first transcranial magnetic stimulation (TMS) center in Kuwait? What advice do you have for clinicians who want to help reduce the stigma that surrounds mental health? In this episode, psychiatrist Dr. Mohammad Alsuwaidan address these questions and much more. Dr. Mohammad Alsuwaidan MD, MPH, FRCPC, DipABPN is an assistant professor of psychiatry at the University of Toronto in Canada. He is also the founder and clinical director of MindWell, a leading regional private mental health center based in Kuwait and the Chief Medical Officer of TMS NextGen a TMS training and operations management company based in Dubai. Dr. Alsuwaidan completed his psychiatry residency, mood & anxiety disorders fellowship and medical education fellowship at the University of Toronto. He also trained in mood disorders at the Stanford University bipolar clinic and the Tufts Medical Center mood disorders clinic. He completed a Masters of Public Health (MPH) at Johns Hopkins University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada, a Diplomate of the American Board of Psychiatry and Neurology and is certified in public health by the National Board of Public Health Examiners. He was the host for the 2022 NEI Congress, and he is widely-sought internationally as a speaker, educator and anti-stigma advocate in mental health.

When it comes to Alzheimer’s disease, what is the amyloid cascade hypothesis? How has this theory impacted drug development for Alzheimer’s disease over the past three decades? With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment. Today, Dr. Andy Cutler interviews Dr. Stephen Stahl on the current state of Alzheimer’s disease and the amyloid controversy. Let’s listen in to Part 1 of our theme: Alzheimer’s Disease and the Amyloid Controversy Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, we invite Dr. Christine Moutier of the American Foundation for Suicide Prevention, along with Christopher Thomas and Martha Thomas of the Defensive Line so they could have a chance to address some of your unanswered questions from their presentation on suicide prevention at the 2022 NEI Congress titled “Reasons to Hope: Evidence-Based Actions for Suicide Prevention. Christine Moutier serves as the chief medical officer for the American Foundation for Suicide Prevention (AFSP) and knows the impact of suicide firsthand. After her own lived experience and losing physician colleagues to suicide, she dedicated herself to fighting this leading cause of death. For the past decade as CMO at AFSP, Dr. Moutier has been leading a nationwide movement fueled by science and grassroots. She has testified before Congress numerous times, presented at the White House and the National Academy of Sciences, and is a frequent expert contributor for major media outlets.   Martha co-founded The Defensive Line with Chris and her son, Solomon to honor her daughter, Ella, and to bring a message of hope and help to other at-risk young people. She is the roots of her family and believes and demonstrates fundamentally that connection is our greatest source of strength. She recently stepped out of the classroom to work full-time in her role as the Chief Education Officer for the organization. While she is no longer in the classroom, she is still teaching others important lifesaving skills. As a teacher and educator for 30 years, Martha brings a deep understanding of the profession to The Defensive Line. Martha resides in Coppell, Texas with her husband, Chris, and two rescue dogs Mickey and Rebel. She is a marathoner and devoted friend to many, as well as a huge fan of the New York Jets for whom her son, Solomon, plays as a defensive lineman. As a senior executive at Procter & Gamble, Frito-Lay, and Alberto Culver among others, Chris brought a drive for excellence to his work, earning recognition and industry awards including Salesperson of the Year and Supplier of the Year. He is a member of the Board of Directors of the American Foundation for Suicide Prevention, as well as Touched By Suicide (TBS) board member, AFSP Project 2025 board member, and College of Wooster Ad Hoc Alumni Trustee. Martha, Chris, and Solomon were recipients of the 2019 AFSP Lifesaver Award. During his 30-plus years in corporate management of consumer goods and products, both domestically and internationally. A gifted college athlete, Chris played an integral role in coaching and developing the athletic achievements of his children, Ella and Solomon. In addition to receiving the AFSP Lifesaver Award in 2019 with Solomon, Martha and Chris are active with suicide survivors organizations, have spoken at the 2022 Neuroscience Education Institute Congress, Texas Association of Gifted and Talented Conference, United Healthcare Suicide Prevention Town Hall and many others.

Why is measurement-based care so important to the overall treatment of schizophrenia? What are the most important reasons for using plasma antipsychotic levels when treating schizophrenia patients?   In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the importance of measuring plasma levels when administering antipsychotics.   With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on complex treatment-resistant psychotic disorders.  Episodes to be released under this theme include:  Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings  Part 2: The Clozapine Handbook with Dr. Jonathan Meyer  Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer  Subscribe to the NEI Podcast, so that you don’t miss another episode! 

What did we learn about the relationship between PTSD and the gut microbiome this year? What are pherines? How can they reduce anxiety, according to research that was published this year? What other exciting news about psychopharmacology do you have to share with us? In this episode, Dr. Cutler addresses these questions and so much more about this past year in psychopharmacology. Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996. Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials. Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry.

Why is clozapine underutilized, even though it’s a very effective antipsychotic for treatment-resistant schizophrenia? What led you to write The Clozapine Handbook? In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the use of clozapine in clinical practice.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings Part 2: The Clozapine Handbook with Dr. Jonathan Meyer Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, Dr. Mary Kimmel answers your important questions from her presentation: No Woman, No Cry: Advancements in the Diagnosis and Treatment of Postpartum Depression.

In this episode, Dr. Napoleon Higgins answers your important questions from his presentation, To the Moon and Back: Pediatric ADHD.

In this episode, Dr. Andy Cutler addresses your unanswered questions from his presentation, New Kids on the Block: Novel Receptor Science in the Treatment of Major Depressive Disorder.

In this episode, Dr. Jeffrey Strawn answers your most pressing questions from his presentation, Blue Genes: Using Pharmacogenetics to Guide Prescribing.

In this episode, Dr. Adelaide Robb addresses your unanswered questions from her presentation: Assessment and Treatment of Pediatric Impulsive Aggression: A Transdiagnostic Issue.

What are the early diagnostic stages of Alzheimer’s disease? What sort of brain changes can occur up to 20 years prior to symptoms of Alzheimer’s disease? In this episode, Dr. Danielle Goldfarb addresses these questions and much more! She shares the most current research on dementia and geriatrics relevant to clinical practice. She also shares resources for early diagnosis of dementia and treating mental health in geriatrics. Dr. Danielle Goldfarb is an Assistant Professor of Neurology and Psychiatry at the University of Arizona and a dual board-certified neurologist and psychiatrist at the Banner Sun Health Research Institute and Cleo Roberts Memory Center in Sun City, AZ.  Dr. Goldfarb cares for patients and families with Alzheimer’s disease and related dementias (ADRD). She leads several Alzheimer’s clinical trials and is involved in research efforts to explore the neuropathologic substrates of early neuropsychiatric symptoms in ADRD, to improve the safety and efficiency of  the collection of cerebrospinal fluid biomarkers in older adults, and to expand access to ADRD care and research by underserved communities.

What made you both want to write the book “Management of Complex Treatment-Resistant Psychotic Disorders? What are some of the most challenging components to treat, when it comes to complex psychosis and how are these addressed in the book? In this episode, Dr. Andrew Cutler interviews Dr. Michael Cummings on how to manage complex treatment-resistant psychotic disorder. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings Part 2: The Clozapine Handbook with Dr. Jonathan Meyer Part 3: Don’t Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are some of the major differences between intravenous or IV ketamine and intranasal esketamine? How are you building on these research findings and what associated avenues have been explored? In this episode, we interview the poster winner from last year’s NEI Congress, Dr. Balwinder Singh on his research comparing intravenous ketamine and intranasal esketamine. The study, conducted at Mayo Clinic rendered interesting findings that may be important for clinicians. Dr. Balwinder Singh is a Consultant and Assistant professor in the Department of Psychiatry at Mayo Clinic in Rochester, Minnesota. He is a psychiatrist specializing in mood disorders, and his research is focused on novel treatments for treatment-resistant depression and identifying biomarkers for ketamine response.  He is also involved in the ketamine and esketamine clinic practice at the Mayo Clinic Depression Center.   This is one of the first studies to highlight a faster response to intravenous ketamine as compared to intranasal esketamine in an observational study. Title: Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study Byline: Balwinder Singh; Simon Kung; Vanessa Pazdernik; Kathryn M. Schak; Jennifer Geske; Phillip J. Schulte; Mark A. Frye; Jennifer L. Vande Voort Citation: J Clin Psychiatry 2023;84(2):22m14548 DOI: https://doi.org/10.4088/JCP.22m14548 URL: Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study | Psychiatrist.com

  In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about novel agents in development for Major Depressive Disorder or MDD. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-MDD. Learning Objectives: After completing this educational activity, you should be better able to: Describe novel mechanisms of action of agents under investigation for the treatment of depression Explain the potential implications of novel rapid-acting and multi-modal agents in optimizing outcomes for patients with unipolar depression Integrate newly available options for depression into clinical practice Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Vladimir Maletic, MD, MS Clinical Professor of Psychiatry, University of South Carolina School of Medicine, Greenville, SC Consultant/Advisor: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Sage Therapeutics, Inc. Released: September 26, 2022     CME/CE credit expires: September 26, 2025

Description: What is an Enhanced Treatment Program or ETP? What is the history behind it and how is it used today? In this episode, Dr. Andrew Cutler interviews Dr. Carolina Klein about how to diagnose and treat antisocial personality disorder. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Decriminalizing Mental Illness with Dr. Katherine Warburton Part 2: The Antisocial Personality Disorder Spectrum: Diagnosis and Treatment with Dr. James Knoll Part 3: Intensive Level Care for Violent Patients with Serious Mental Illness with Dr. Carolina Klein Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, we take a look back at some of the incredible women in medicine we’ve had on the NEI Podcast over the years. We begin with reflecting on Episode 69: A Beacon of Hope in the Storm of Mental Illness: An Update on Suicide Awareness and Prevention with Dr. Christine Moutier. Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention. To hear the full episode click on the link below: https://neiglobal.libsyn.com/a-beacon-of-hope-in-the-storm-of-mental-illness-an-update-on-suicide-awareness-and-prevention-with-dr-christine-moutier Next, we turn to Episode 77: Mental Health in the Muslim Community with Dr. Mona Masood. Dr Masood is a psychiatrist and she is on the Board of Directors at the Muslim Wellness Foundation. To listen to the full episode click on the link below: https://neiglobal.libsyn.com/e77-mental-health-in-the-muslim-community-with-dr-mona-masood We then return to our interview with Dr. Christina Girgis in Episode 79: Gender Disparities in the Mental Health Profession with Dr. Christina Girgis. Dr. Girgis is certified by both the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She is currently the Medical Director of the Consultation-Liaison Psychiatry Service at Edward Hines, Jr. VA Hospital and the Associate Training Director of the Psychiatry Residency Program at Loyola University Medical Center. To hear the complete episode click on the link below: https://neiglobal.libsyn.com/e79-gender-disparities-in-the-mental-health-profession-with-dr-christina-girgis Next, we reflect on Episode 82: Refreshing Perspectives on Recovery: September is National Recovery Month with Dr. Nzinga Harrison. Dr. Harrison is Board-Certified in both Adult General Psychiatry and Addiction Medicine and she is the Chief Medical Officer and Co-founder of Eleanor Health. To hear the full episode, click on the link below: https://neiglobal.libsyn.com/e82 We then turn to Episode 101: Ooh Child, Things are Going to Get Easier: Managing Pediatric Anxiety with Dr. Krystal Lewis. Dr. Lewis is clinical psychologist with the Section on Development and Affective Neuroscience (SDAN) at the National Institute of Mental Health (NIMH). She is also a member of the Stigma Scientific Interest Group (SIG), and the NIMH Anti-Racism Task Force at the National Institute of Health (NIH). For the complete episode, click on the link below: https://neiglobal.libsyn.com/e101-ooh-child-things-are-going-to-get-easier-managing-pediatric-anxiety-with-dr-krystal-lewis Finally, we reflect on Episode 150: Blazing Trails to Breakdown Structural Racism and Improve Black Mental Health with Dr. Sarah Vinson. She is triple-board certified in adult, child & adolescent, and forensic psychiatry and the founder of the Lorio Psych Group. To listen to the complete episode, click on the link below: https://neiglobal.libsyn.com/blazing-trails-to-breakdown-structural-racism-and-improve-black-mental-health We hope you’ve enjoyed a look back at some of the most amazing women in medicine we’ve had on our show!

In this episode, Dr. Andrew Cutler interviews Dr. Karl Doghramji on best practices for the treatment and management of insomnia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Sleep Learning Objectives: After completing this educational activity, you should be better able to: Utilize assessment tools in the diagnosis of insomnia Address challenges in the pharmacologic treatment of insomnia Implement evidence-based pharmacological treatments for insomnia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content were required to disclose all relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD  Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris IntervieweeKarl Doghramji, MDProfessor, Department of Psychiatry & Human Behavior; Associate Professor, Departments of Neurology and of Medicine; Medical Director, Jefferson Sleep Disorders Center; Program Director, Fellowship in Sleep Medicine; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PAResearch/Grant: Harmony, Inspire Consultant/Advisor: Axsome, Eisai, Jazz, Harmony, Idorsia, Imbrium, Inspire Stockholder: Merck Pre-Interview AuthorSabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency, and strategies for understanding and reducing implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Eisai. Released: August 31, 2022          CE credit expires: August 31, 2025

What is the difference between psychopathy and antisocial personality? What is known about gender differences when it comes to antisocial personality disorder? In this episode, Dr. Andrew Cutler interviews Dr. James Knoll about how to diagnose and treat antisocial personality disorder. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on decriminalizing mental illness. Episodes to be released under this theme include: Part 1: Decriminalizing Mental Illness with Dr. Katherine Warburton Part 2: The Antisocial Personality Disorder Spectrum: Diagnosis and Treatment with Dr. James Knoll Part 3: Intensive Level Care for Violent Patients with Serious Mental Illness with Dr. Carolina Klein Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, we take a look back at Dr. Roger McIntyre’s presentation on the treatment spectrum for depression and mania. In this sneak peek, Dr. McIntyre focuses on the current treatments that are available for the bipolar disorder spectrum. He addresses the implications of comorbid substance abuse with respect to pharmacological treatments. He also discusses lifestyle factors that can be preventative against cognitive decline associated with mood disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

In today’s CME episode, Dr. Andrew Cutler will be interviewing Dr. Leslie Citrome about the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD03 Learning Objectives: After completing this educational activity, you should be better able to: Recognize the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia Individualize treatment regimens for patients with tardive dyskinesia, utilizing FDA-approved medications Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva   IntervieweeLeslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Reviva (options)   Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.   The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: July 27, 2022     CME/CE credit expires: July 27, 2025

In this episode, Dr. Andrew Cutler interviews Dr. Katherine Warburton about the history of criminalization of serious mental illness, the efforts to decriminalize mental illness, and the development and success of diversion programs. Dr. Katherine Warburton is Medical Director/Deputy Director of Clinical Operations for the California Department of State Hospitals. Prior to that, she was the Chief of Forensic Psychiatry at Napa State Hospital. She is on the volunteer clinical faculty of the UC Davis Division of Psychiatry and the Law. With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on decriminalizing mental illness. Episodes to be released under this theme include: Part 1: Decriminalizing Mental Illness Part 2: Managing the Unique Challenges of Correctional Psychiatry Part 3: The Intensive Treatment Setting and Special Cases in Forensic Psychiatry Subscribe to the NEI Podcast so that you don’t miss another episode! Link to “Decriminalizing Mental Illness” by Drs. Warburton and Stahl: https://www.amazon.com/Decriminalizing-Mental-Illness-Katherine-Warburton/dp/1108826954/ref=sr_1_1?crid=18XJ6RE7Y5X5M&keywords=warburton+stahl&qid=1657746214&sprefix=warburton+stahl%2Caps%2C112&sr=8-1

How did Fountain House come to be? What is the history behind it? What does it mean to be a Fountain House member? In this fascinating podcast, we hear from three experts who work with Fountain House to reduce stigma for people with serious mental illness, improve education, foster a community and provide resources for members of Fountain House to thrive and live fulfilling lives. Fountain House is a national mental health nonprofit fighting to improve health, increase opportunity, and end social and economic isolation for people impacted by mental illness. Drawing on more than 200 community-based social rehabilitative programs inspired by Fountain House and known as clubhouses - to reflect an insistence on belonging and acceptance - in nearly 40 states and with more than 60,000 members, they are leading a national movement for the dignity and rights of people with serious mental illness. Jeanie Tse, MD is the Senior Medical Director at Fountain House and an Associate Professor of Psychiatry at the NYU School of Medicine. She brings to Fountain House her expertise in integrated health care for people with serious mental illnesses, developed in the course of her work as the former Chief Medical Officer at the Institute for Community Living. She has a special interest in disrupting the impact of trauma on health outcomes, with an overarching aim to “bridge the gap” between academic psychiatry and the clinical challenges of under-resourced communities.  Francesca Pernice, PhD is an associate professor in Educational Psychology and Director of Counseling Psychology at Wayne University's College of Education. Her areas of expertise include social and interpersonal relationships, clubhouse community recovery programs, recovery from serious mental illness, and research in mental health, and program evaluation. She instructs graduate courses in the area of adult psychopathology, ethics, and educational psychology. She serves as advisor for PhD students in the School Psychology PhD Concentration and Learning and Instructional Sciences PhD concentration within the department of Educational Psychology. Her areas of expertise include family psychoeducation about serious mental illness, and research of psychiatric rehabilitation programs known as Fountain House Clubhouses. Cyrus Daniel Napolitano is a member of Fountain House who has served on their Board of Directors, the Council, a think-tank that focuses on innovation, training, education, research, public policy, advocacy, and technology. He is currently Co-Director of the Clubhouse New York Coalition that represents 14 clubhouses in NYC and in New Jersey. He is also working to foster the development of community-based mental health programs in low- to middle-income countries.  Fountain House website: https://www.fountainhouse.org/

In this episode, Dr. Andrew Cutler interviews Dr. Tiffany Greenwood about the intersection of genetics, personality traits, temperament and cognitive traits in bipolar disorder and creativity. What is psychiatric genetics? What is known about dopamine’s role in creativity? Dr. Tiffany Greenwood address these questions and much more. Dr. Greenwood received her B.S. in Molecular Biology and her Ph.D. in Biomedical Sciences from UC San Diego, with an emphasis in psychiatric genetics. She then augmented her molecular genetic background with postdoctoral training in applied statistical genetics and acquired supplemental training in clinical psychopathology through a Career Development Award from the National Institute of Mental Health (NIMH). She joined the Department of Psychiatry at UC San Diego in 2007 and is currently an Associate Professor. As the Director of the Laboratory for Psychiatric Spectrum Research, Dr. Greenwood’s research focuses on the use of dimensional and intermediate phenotypes, as well as clinical subphenotypes, to reduce clinical heterogeneity and refine the genetic signal. Such measures provide increased specificity, both within and across diagnostic categories, as well as a better reflection of the underlying biological processes. In this vein, Dr. Greenwood participates in a number of large-scale collaborations aimed at identifying genetic risk variants for psychiatric illness, including the Consortium on the Genetics of Schizophrenia (COGS), the Bipolar Genome Study (BiGS), and the Psychiatric Genomics Consortium (PGC). Her research in this area has been supported by a NARSAD Young Investigator Award for the development and utilization of a customized candidate gene array for schizophrenia and related phenotypes, as well as a K01 from the NIMH aimed at quantifying and interpreting the overlapping and unique aspects of bipolar disorder and schizophrenia. Dr. Greenwood has served as a Principal Investigator or Co-Investigator on a number of University and NIH-funded grants, including a current study exploring bipolar disorder as a dimensional phenotype existing at the extreme of normal population variation in positive traits, such as temperament, personality, creativity, and cognitive flexibility. Dr. Greenwood also recently received funding for a pilot project to implement a comprehensive screening and risk assessment program at UC San Diego. This project aims identify behavioral, environmental, and genetic factors associated with risk for mental health conditions, particularly mood disorders and suicide, and develop a risk prediction model to be used for early intervention. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko Part 3: History of Creative Famous Individuals with Bipolar Disorder Subscribe to the NEI Podcast, so that you don’t miss another episode!

How has your work in psychiatry consulting and education made a difference in fighting racism on both the individual and structural level? What is your book “Social (In)Justice and Mental Health” about? In this episode, Dr. Sarah Vinson shares her extensive experience and perspective on the intersection between child and adolescent psychiatry, forensics, and the fight for social justice in mental health.   Dr. Sarah Y. Vinson is a physician who is triple-board certified in adult, child & adolescent, and forensic psychiatry. She is the founder of the Lorio Psych Group, an Atlanta, GA based mental health practice providing expert care and consultation. Dr. Vinson is also the founder of Lorio Forensics, which provide consultation in a wide variety of cases in criminal, civil and family court cases. After graduating from medical school at the University of Florida with Research Honors and as an Inductee in the Chapman Humanism Honors Society, she completed her general psychiatry training at Cambridge Health Alliance/Harvard Medical School. While there, she also received specialized training in trauma through the Victims of Violence Program. She then returned to the South to complete fellowships in both child & adolescent and forensic psychiatry at Emory University School of Medicine. In addition to providing mental health care services such as psychotherapy, consultation and psychopharmacology through her private practice, Dr. Vinson is an Associate Clinical Professor of Psychiatry and Pediatrics at Morehouse School of Medicine. Just two years after joining the faculty she was honored as Psychiatry and Faculty of the Year in 2015. She is also Adjunct Faculty at Emory University School of Medicine. She has been elected and/or appointed to national and statewide office by her professional peers. She is the Past President of the Georgia Council on Child and Adolescent Psychiatry, and the Treasurer of the Georgia Psychiatric Physicians Association. Additionally, she is an Advisor for the Judges Psychiatry Leadership Initiative.  She has been a speaker at national conferences including the American Psychiatric Association Annual Meeting, the American Academy of Child and Adolescent Psychiatry Annual Meeting and The National Urban League Annual Meeting. Dr. Vinson has received numerous awards in recognition of her service and leadership including the University of Florida College of Medicine Outstanding Young Alumna Award and the APA Jeanne Spurlock Minority Fellowship Alumna Achievement Award. Resources: https://drsarahvinson.com/ Link to “Social (In) Justice in Mental Health”: https://www.amazon.com/Social-Injustice-Mental-Health-Ruth/dp/1615373381/ref=sr_1_1?dchild=1&keywords=social%20injustice%20and%20mental%20health&qid=1608052484&sr=8-1

In this episode, Dr. Andrew Cutler interviews Dr. Diana Perkins on best practices for shared decision making and patient education. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD02 Learning Objectives: After completing this educational activity, you should be better able to: Educate patients and family members with mood disorders and schizophrenia about the symptoms of tardive dyskinesia Address psychosocial and quality-of-life concerns related to tardive dyskinesia in patients with mood disorders and schizophrenia Include patients, caregivers, and family members in shared decision-making when applicable to optimize patient outcomes before and during of treatment of tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva  Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Diana Perkins, MD, MPH Professor, Department of Psychiatry; Medical Director, Outreach and Support Intervention Services; University of North Carolina School of Medicine, Chapel Hill, NC  Consultant/Advisor: Alkermes, Karuna  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies, and strategies for understanding and reducing implicit bias can be found in this can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: May 27, 2022          CE credit expires: May 27, 2025  

In this episode, Dr. Andrew Cutler interviews Mr. Marko Perko and Dr. Stephen Stahl about their newly released book “Tesla: His Tremendous and Troubled Life” and the intersection between Tesla’s genius, creativity, and bipolar disorder. How is your book unique from any book that’s been written on Tesla before? What is the main message that you’d like readers to take away from this book? In this episode Mr. Perko and Dr. Stahl address these questions and much more! Marko Perko is a graduate of the University of Southern California. He has always had an insatiable thirst for knowledge of all types, and as such, he is highly regarded as a modern-day Renaissance man, author, historian, polymath, polemicist, and history communicator. He is the author of the critically acclaimed and wildly popular book “Did You Know That . . .?” He is also a novelist and the writer of an international bestselling knowledge-based board game, as well as the creator of the Cultural Enrichment Programs education series, and a software developer―Krypti.com. Perko has written for and edited numerous publications, and he has worked as a columnist, speechwriter, composer, musician, lecturer, and playwright. He is a member of The Authors Guild; the Biographers International Organization; the American Society of Composers, Authors and Publishers; Broadcast Music, Inc.; the Institution of Engineering and Technology; the British Library; and the Organization of American Historians. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko Part 3: History of Creative Famous Individuals with Bipolar Disorder Subscribe to the NEI Podcast, so that you don’t miss another episode!   Link to “Tesla: His Tremendous and Troubled Life”: https://www.amazon.com/Tesla-His-Tremendous-Troubled-Life-ebook/dp/B09QMPH6MG/ref=sr_1_1?crid=O0UAHNGC8Z0J&keywords=tesla+by+marko+perko&qid=1652729759&sprefix=tesla+by+marko+perko%2Caps%2C113&sr=8-1

Why are you so passionate about mental health care in the primary care setting? When did you first experience your own challenges with mental health? What is your advice for mental health professionals and medical professionals when it comes to prioritizing their own mental health? In this episode, Dr. Linda Gask answers these questions and much more about her own personal journey with mental health as a provider and a patient. Dr. Linda Gask is a writer and a psychiatrist. She retired from being a consultant in the National Health Service and an academic at the University of Manchester some years ago. However she returned for a year during the coronavirus pandemic to work with the Greater Manchester Bereavement Service and she is now Emerita Professor of Primary Care Psychiatry at the University of Manchester. She has been an advisor to the World Health Organization and was awarded the President’s Medal by the Royal College of Psychiatrists in 2017. She has experienced anxiety and depression throughout her adult life and she has written two memoirs called “The Other Side of Silence” and “Finding True North: The Healing Power of Place.” She was born in England, trained in Scotland where she currently resides. Resources: https://lindagask.com/ The Other Side of Silence: https://www.amazon.com/Other-Side-Silence-Psychiatrists-Depression-ebook/dp/B014I1F0QU/ref=sr_1_1?qid=1649898250&refinements=p_27%3ALinda+Gask&s=books&sr=1-1 Finding True North: The Healing Power of Place: https://www.amazon.com/Finding-True-North-Healing-Power/dp/B09VTJFDXV/ref=sr_1_5?qid=1649898250&refinements=p_27%3ALinda+Gask&s=books&sr=1-5  

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation: ADHD, Female Hormones, and Menopause: The Little We Know from Research at the 2022 NEI Synapse.

In this episode, Carmen Kosciek discusses your most important questions from her presentation: Uploading Progress: Technology in Psychiatry at the 2022 NEI Synapse.

In this episode, Dr. Thomas Schwartz addresses your unanswered questions from his presentation: Too Much or Too Little: Sleep Issues and How to Treat Them at the 2022 NEI Synapse by Dr. Thomas Schwartz.

In this episode, Dr. Roger McIntyre addresses your most pressing questions from his presentation: Bipolar Disorder Rainbow: The Spectrum of Treatments for Depression and Mania at the 2022 NEI Synapse.

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on creativity in bipolar disorder. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko Part 3: History of Creative Famous Individuals with Bipolar Disorder Subscribe to the NEI Podcast, so that you don’t miss another episode!

What led you to pursue a career in auditory neuroscience and what is the mission behind your laboratory, Brainvolts? What is the effect of bilingualism on Alzheimer’s disease? How can sound be used for the assessment of traumatic brain injury and other neurological conditions? In this episode, Dr. Nina Kraus addresses these questions and much more about the clinical applications for auditory neuroscience research. Her laboratory at Northwestern University, Brainvolts has discovered how to measure the biology of auditory processing with unprecedented precision. The implications of the research conducted there extends beyond the laboratory to schools, community centers, and clinics. Nina Kraus, Ph.D. is a professor at Northwestern University who studies the biology of auditory learning. Through a series of innovative studies involving thousands of research participants from birth to age 90, her research has found that our lives in sound, for better (musicians, bilinguals) or worse (language disorders, concussion, aging, hearing loss), shape auditory processing. She continues to conduct parallel experiments in animal models to elucidate the mechanisms underlying these phenomena. Never having accepted a lack of technology as a roadblock to scientific discovery, Kraus has invented new ways to measure the biology of sound processing in humans that provide precision and granularity in indexing brain function. With her technological innovations she is now pushing science beyond the traditional laboratory by conducting studies in schools, community centers, and clinics. Using the principles of neuroscience to improve human communication, she advocates for best practices in education, health, and social policy. Dr. Kraus is the author of the book “Of Sound Mind: How our Brain Constructs a Meaningful Sonic World”. Resources: Link to “Of Sound Mind: How our Brain Constructs a Meaningful Sonic World”: https://www.amazon.com/Sound-Mind-Brain-Constructs-Meaningful/dp/0262045869#:~:text=Of%20Sound%20Mind%3A%20How%20Our,9780262045865%3A%20Amazon.com%3A%20Books Link to Brainvolts: https://brainvolts.northwestern.edu/about-us/ Link to BEAMS hypothesis: https://brainvolts.northwestern.edu/wp-content/uploads/2021/07/Kraus_BEAMS_2021-1.pdf

In this episode, Dr. Andrew Cutler interviews Dr. Rajnish Mago on best practices for early detection and screening for tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD01 Learning Objectives: After completing this educational activity, you should be better able to: Conduct regular screenings for symptoms of tardive dyskinesia in patients with mood disorders and schizophrenia Employ evidence-based screening tools in the differential diagnosis of tardive dyskinesia, including the Abnormal Involuntary Movement Scale  Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.   Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented. Interviewer Andrew J. Cutler, MDClinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva  Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Rajnish Mago, MD  Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY  Clinical Assistant Professor, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA  Editor-in-Chief, Simple and Practical Medical Education  No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: March 23, 2022          CE credit expires: March 23, 2025

In what ways do we have the power to influence neuroplasticity? How would you define pathologic or dark neuroplasticity? Are there ways to enhance or preserve our circuits as a form of adaptive neuroplasticity? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on dark neuroplasticity. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Power of Dark Persuasion with Dr. Joel Dimsdale Part 2: Dark Psychiatry and Social Media with Dr. Donatella Marazziti Part 3: Good and Bad Neuroplasticity Subscribe to the NEI Podcast, so that you don’t miss another episode!

What was your personal experience with Match Day? What has your personal experience been like being transgender and how has this impacted your professional track when it comes to clinicians treating patients who are nonbinary or transgender? In this podcast episode, Dr. Mulkey addresses these questions and more about psychiatry residency and Match Day. Dr. Nat Mulkey, MD is a psychiatrist and first-year resident at the University of Vermont Medical Center. They graduated from Boston University School of Medicine, where they worked closely with faculty on LGBTQI+ curricula in undergraduate medical education and related initiatives. Their interests include child and adolescent psychiatry, LGBTQI+ mental health, pharmacology, addiction, and first break psychosis. Their hobbies are creative writing and trail running.  Articles by Nat Mulkey, MD: The Search for a Cause of Transness Is Misguided - Scientific American Misgendering in Medicine: How to Improve Care of Transgender and Gender Non-Binary Patients » in-Training, the online peer-reviewed publication for medical students https://www.psychiatrictimes.com/view/mental-health-crisis-ground-level https://www.aamc.org/news-insights/finding-my-community-gaymedtwitter Resources for LGBTQ+ Clinicians and Caregivers: Gender Spectrum Homepage - Gender Spectrum Transgender Professional Association for Transgender Health | Trans Health by Trans People (tpathealth.org) Education & Training - Fenway Health: Health Care Is A Right, Not A Privilege. Resources for LGBTQ+ Patients:  https://www.lgbtqiahealtheducation.org/resources/ https://www.uvmhealth.org/childrens-hospital/pediatric-specialties/transgender-youth-program/transgender-resources https://www.uvm.edu/health/transhealth

Which unique factors of social media place it in a powerful position to influence people? How is marketing used as mass persuasion? In this episode, Dr. Andrew Cutler interviews Dr. Donatella Marazziti on dark persuasion and social media. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Power of Dark Persuasion with Dr. Joel Dimsdale Part 2: Dark Psychiatry and Social Media with Dr. Donatella Marazziti Part 3: Good and Bad Neuroplasticity Subscribe to the NEI Podcast, so that you don’t miss another episode!

What was your experience like as co-chair of the Revision Subcommittee and DSM-5-TR editor? How was the impact of racism and discrimination on the diagnosis and manifestations of mental disorders addressed? In this important and timely episode, Dr. Michael First addresses these questions and much more about the upcoming release of the DSM-5-TR in March 2022. Dr. Michael B. First is a Professor of Clinical Psychiatry at Columbia University and a Research Psychiatrist at the Biometrics Department at the New York State Psychiatric Institute. He maintains a schematherapy and psychopharmacology practice in Manhattan. Dr. First is a nationally and internationally recognized expert on psychiatric diagnosis and assessment issues and has conducted expert forensic psychiatric evaluations in both civil and criminal matters, including the 2006 trial of the 9/11 terrorist Zacarias Moussaoui. Dr. First is the Editorial and Coding Consultant for the DSM-5, the chief technical and editorial consultant on the World Health Organization's ICD-11 revision project and is an external consultant to the NIMH Research Domain Criteria project. Dr. First has an undergraduate degree in Electrical Engineering and Computer Science from Princeton University, received a Masters in Computer Science and a Medical Degree from the University of Pittsburgh, completed his psychiatry residency at Columbia University, and also completed a fellowship in Biometrics Research under the direction of his mentor, Dr. Robert Spitzer. He was the Editor of the DSM-IV-TR, the Editor of Text and Criteria for DSM-IV and the American Psychiatric Association (APA)'s Handbook on Psychiatric Measures. He has co-authored and co-edited a number of books, including A Research Agenda for DSM-V, the DSM-IV-TR Guidebook, the DSM-5 Handbook for Differential Diagnosis, and the Structured Clinical Interview for DSM-5 (SCID-5). Notably, he is also the co-chair of the Revision Subcommittee and Editor of the DSM-5-TR

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on best practices for switching antipsychotics. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Switch Learning Objectives: After completing this educational activity, you should be better able to: Understand the relevance of receptor binding properties and pharmacokinetic profiles when switching antipsychotics Follow evidence-based guidelines when switching antipsychotics Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Stephen M. Stahl, MD, PhD, DSc (Hon.)  Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA Grant/Research: Acadia, Avanir, Braeburn, Intra-Cellular, Ironshore, Lilly, Neurocrine, Otsuka, Shire, Sunovion Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Arbor, Axovant, Axsome, Celgene, ClearView, Concert, EMD Serono, Eisai, Ferring, Impel, Intra-Cellular, Ironshore, Janssen, Karuna, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Relmada, Sage, Servier, Shire, Sunovion, Takeda, Taliaz, Teva, Tonix, Tris, Vifor Speakers Bureau: Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, Takeda, Teva, Vertex Board Member: Genomind Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout. Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies. Released: January 26, 2022          CE credit expires: January 26, 2025          

How did you come about writing “Dark Persuasion”? What exactly is brainwashing? What are the common features of torture and coercive persuasion? In this episode, Dr. Andrew Cutler interviews Dr. Joel Dimsdale about his new book, “Dark Persuasion”. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Power of Dark Persuasion with Dr. Joel Dimsdale Part 2: Dark Psychiatry and Social Media with Dr. Donatella Marazziti Part 3: Good and Bad Neuroplasticity Subscribe to the NEI Podcast, so that you don’t miss another episode!

What exactly is seasonal affective disorder (SAD)? What are some of the most common symptoms?  In this episode, Dr. Jade Wu addresses these questions and much more about SAD. Jade Wu, PhD, DBSM, is a Board-certified behavioral sleep medicine specialist and researcher at Duke University School of Medicine. Her current research focuses on treating sleep disorders in those with chronic illness. She is a frequent guest on popular TV, radio and podcast shows like NPR and ABC, and her work is featured in publications like New York Times and Huffington Post. She formerly hosted the popular Savvy Psychologist podcast. Dr. Wu’s mission is to spread the gift of sleep, so that people can be their healthiest, organizations can be their most innovative, and societies can sleep their way towards justice and healing.

In this episode, Dr. Andrew Cutler interviews Dr. Joseph Goldberg on the management of metabolic side effects associated with antipsychotics.  Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MET  Learning Objectives: After completing this educational activity, you should be better able to: Differentiate antipsychotic medications based on risk for metabolic side effects Monitor patients for metabolic side effects Implement management strategies to address metabolic side effects  Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   NEI designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest minimum score of 70% is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): application-based contact hours Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™  Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.  Disclosures: All individuals in a position to influence or control content were required to disclose any relevant financial relationships, which were then mitigated prior to the activity being presented.  Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Joseph F. Goldberg, MD   Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY Consultant/Advisor: BioXcel, Intra-Cellular, Lundbeck, Otsuka, Sunovion Speakers Bureau: Allergan/Abbvie, Intra-Cellular, Sage, Sunovion Royalties: American Psychiatric Publishing, Cambridge University Press Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.  Released: December 22, 2021          CE credit expires: December 22, 2024    

Can you explain how the same symptoms may cut across numerous psychiatric disorders and how the same treatment may be efficacious across psychiatric disorders? What areas in psychopharmacology remain the most challenging to treat and why do you think that is? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the future of psychopharmacology. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology? Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology Part 3: The Future of Psychopharmacology Subscribe to the NEI Podcast, so that you don’t miss another episode!

Who is Pear and what are prescription digital therapeutics? Why are PDTs so important to the continuum of care, especially when it comes to mental health? In this fascinating interview, Dr. Andrew Cutler interviews Dr. Corey McMann, the President and CEO of Pear Therapeutics about the importance of this technology in treating mental health. Corey M. McCann, MD, PhD, is the President and CEO of Pear Therapeutics. Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system expertise group, advising clients across the healthcare value chain.

What are some of the new FDA approvals for medications that happened this year? What did we learn about the association between ADHD and Alzheimer’s disease from a nationwide cohort study that was conducted? In this important and timely episode, Dr. Andrew Cutler addresses these questions and many more on the most interesting updates in psychopharmacology in 2021. Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996. Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials. Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry. Resources: This Month in Psychopharmacology: https://www.neiglobal.com/Members/MonthInPsychopharmNew/tabid/508/Default.aspx FDA Clears Technology to Aid in Concussion Diagnosis: https://www.neiglobal.com/Members/MonthInPsychopharmPost/tabid/509/Default.aspx?topic=20527 International League Against Epilepsy Society (AES): https://www.ilae.org/

What was the inspiration behind creating the Fifth Edition video series? What are your best learning strategies for studying psychopharmacology? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the Fifth Edition Video Series and about the most effective learning strategies for psychopharmacology! With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology? Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology Part 3: The Future of Psychopharmacology Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, Dr. Jeffrey Strawn addresses your unanswered questions from his presentation: Re-Counting Neurobiological Treatment Advances of Obsessive-Compulsive Disorder.    Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents.In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders. 

In this episode, Dr. Manpreet Singh answers your unaddressed questions from her presentation: It's a Woman's World: Exploring Female Mental Health Issues at the 2021 NEI Congress.    Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders.Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009.   Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.

In this episode, Dr. Napoleon Higgins and Dr. Rona Hu address your most pressing questions from their presentation on cultural humility at the 2021 NEI Congress.    Dr. Napoleon Higgins is a child, adolescent and adult psychiatrist in Houston, Texas. He is the owner of Bay Pointe Behavioral Health Services and South East Houston Research Group. He is the President of the Black Psychiatrists of Greater Houston, Past President of the Caucus of Black Psychiatrists of the American Psychiatric Association and Past President of the Black Psychiatrists of America, Inc.Dr. Higgins is co-author of How Amari Learned to Love School Again: A Story about ADHD, Mind Matters: A Resource Guide to Psychiatry for Black Communities and author of Transition 2 Practice: 21 Things Every Doctor Must Know in Contract Negotiations and the Job Search. He also specializes in nutrition and health to improve patients’ lives mentally and physically. He emphasizes that good mental and physical health are key in the practice of psychiatry and medicine.   Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology.Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998. Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.

In this episode, Dr. Charles Scott addresses some of your unanswered questions from his presentation on cannabis and violence.    Dr. Scott is Chief, Division of Psychiatry and the Law, Forensic Psychiatry Fellowship Training Director, and Professor of Clinical Psychiatry at the University of California, Davis Medical Center in Sacramento, California. He is Board Certified in Forensic Psychiatry, General Psychiatry, Child and Adolescent Psychiatry, and Addiction Psychiatry. Dr. Scott has served as a forensic psychiatric consultant to jails, prisons, maximum security forensic inpatient units, California Department of State Hospitals, and as a consultant to the National Football League (NFL) providing training on violence risk assessment for NFL counselors.   His research interests include the relationship of substance use to aggression among criminal defendants, on the quality of forensic evaluations of criminal responsibility, child witness testimony, malingering, and assessment of posttraumatic stress disorder. He lectures nationally on the topics of malingering, violence risk assessment, juvenile violence, substance use and violence, the assessment of sex offenders, correctional psychiatry, DSM-5 and the law, and malpractice issues in mental health.

What are you most excited about, when it comes to this year’s NEI Congress? What is one benefit that both live and virtual attendees will experience at the 2021 NEI Congress? In this episode, we get a sneak peek at what to expect from this highly anticipated event! With the live and virtual simulcast formats, there are a lot of questions and A LOT of excitement! Whether you’ll be joining us in beautiful Colorado Springs or from the comfort of your own home, we have an unforgettable experience planned for you! Listen to this episode to learn more about what’s to come at the 2021 NEI Congress!  

In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre on best practices for using adjunctive treatment for major depressive disorder. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MDD Learning Objectives: After completing this educational activity, you should be better able to: Discuss earlier identification of partial response to anti-depressants and advantages to implementing augmentation strategies sooner to improve treatment outcomes Increase awareness about evidence-based adjunctive treatments that are FDA-approved for depression Examine the pharmacological profiles of approved adjunctive atypical antipsychotic treatments in terms of how they relate to therapeutic benefits and adverse reactions Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this online live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME/CE Credit Types. The following are being offered for this activity: Nursing (ANCC): 1.0 contact hour Pharmacy (ACPE): 1.0 application-based contact hour Physician (ACCME): 1.0 AMA PRA Category 1 Credit ™ Physician Assistant (AAPA): 1.0 Category 1 CME credit Psychology (APA): 1.0 CE credit Social Work (ASWB-ACE): 1.0 ACE CE credit Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for 1.0 AMA PRA Category 1 Credit ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/National Natural Science Foundation of China Consultant/Advisor: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda Speakers Bureau: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck. Released: October 21, 2021          CE credit expires: October 21, 2024    

What are some of the biggest changes that were made to the Fifth Edition and what were the reasons behind these changes? How are mood stabilizers redefined in the Fifth Edition? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about all the updates to the Fifth Edition of Stahl’s Essential Psychopharmacology and all the exciting reasons for those updates. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology? Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology Part 3: The Future of Psychopharmacology Subscribe to the NEI Podcast, so that you don’t miss another episode!

What is unique about collaborative care, when it comes to mental health? Can you share some of the step-by -step guide to implementing the core model in clinical practice for collaborative care? In this episode, Dr. Anna Ratzliff answers these questions and much more! Dr. Anna Ratzliff is a national expert on collaborative care and specifically, on training teams to implement and deliver mental health treatment in primary care settings. Her passion for translating complex research ideas into practical real-world applications began when she received her MD and PhD in Anatomy and Neurobiology as part of the Medical Scientist Training Program at the University of California at Irvine.  She currently is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington where she has developed additional expertise in suicide prevention training, mental health workforce development, adult learning best practices, and mentorship. Dr. Ratzliff is the Director of the UW Psychiatry Resident Training Program, Co-Director of the AIMS Center (Advancing Integrated Mental Health Solutions) and Director of the UW Integrated Care Training Program for residents and fellows. Resources: AIMS Center Website: http://aims.uw.edu/ Implementation Guide: https://aims.uw.edu/collaborative-care/implementation-guide APA Training: https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer on best practices and strategies for improving clinician and patient communication, medication adherence, and collaboration in the community when it comes to treating schizophrenia. Optional CE Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click https://nei.global/POD21-Schiz Learning Objectives: After completing this educational activity, you should be better able to: Demonstrate strategies that involve patient and caregivers in shared informed decision-making for treatment goals Discuss the role of social aspects of community and behavioral health settings on patient experiences and treatment outcomes Address best practices for the use of telemedicine when monitoring treatment for schizophrenia and the use of LAIs Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.25 continuing education hours of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Intra-Cellular, Neurocrine Speakers Bureau: Acadia, Alkermes, Intra-Cellular, Neurocrine, Noven, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck. Released: September 23, 2021          CE credit expires: September 23, 2024

Why do you feel that when it comes to psychopharmacology, knowing how to really interpret the scientific literature is important for clinicians? Why is it important to know whether the clinical characteristics of the subjects resemble or differ from your own patients and to what extent?  In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about why it is important to understand how to interpret the scientific literature and apply it to your clinical practice. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg   https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

What are the most critical components that need to be addressed about social wellbeing when it comes to children returning to school? What signs might alert parents to their children feeling anxious about returning to school? In this timely and important interview. Dr. Manpreet Singh and Dr. Jeffrey Strawn answer these questions and much more! To access the article that Dr. Singh refers to in this episode click here: https://www.nytimes.com/2021/08/20/well/family/back-to-school-fear-tip.html Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders. Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes. Dr. Jeffrey Strawn is Associate Professor in the Department of Pediatrics and in the Department of Psychiatry and Behavior Science at the University of Cincinnati, College of Medicine in Cincinnati, OH. Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents.  In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders.

What is the difference between mediators and moderators, and how do they influence treatment response? Why is it so important, as clinicians to understand the distinction between moderators and mediators and to be aware of their influence on treatment outcomes in the literature?  In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about how moderators and mediators influence clinical outcomes. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg    https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

Why is it so important that many Olympic athletes are speaking out about the importance of mental health, and how can people spread more awareness for mental health concerns in this vulnerable population? What challenges do you face regarding effectively treating mental health conditions in athletes? In this important and timely interview sports psychiatrist, Dr. Greg Mattingly addresses these questions and much more! Dr. Mattingly is a physician and principal investigator in clinical trials for Midwest Research Group. He is also a founding partner of St. Charles Psychiatric Associates where he treats children, adolescents and adults. A St Louis native, he earned his medical degree and received a Fulbright scholarship while attending Washington University. Dr. Mattingly is board certified in adult and adolescent psychiatry and is a Diplomat of the National Board of Medical Examiners. He is an Associate Clinical Professor at Washington University. Dr. Mattingly has been a principal investigator in over 300 clinical trials focusing on ADHD, anxiety disorders, major depression, bipolar disorder and schizophrenia. Having served on numerous national and international advisory panels, Dr. Mattingly has received awards and distinctions for clinical leadership and neuroscience research. Dr. Mattingly currently serves on the board of directors for APSARD-The American Professional Society of ADHD and Related Disorders and is a certified evaluator for both the NFL and MLB. An avid runner and outdoorsman, Dr. Mattingly believes mind, body and spirit are important qualities for him and his family. Resources: www.Midwestresearchgroup.com

In this episode, Dr. Andrew Cutler interviews Dr. Leslie Citrome on some of the challenges that clinicians face when using traditional methods for the treatment of schizophrenia. They discuss the most current research on the development of TAAR1 agonists as a novel class of psychotropic medication for the treatment of schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD21-TAAR1  Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges with traditional methods of treating schizophrenia Discuss the development of TAAR1 agonists as new class of psychotropic medication for the treatment of schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Astellas, Avanir, Axsome, BioXcel, Cadent Therapeutics, Eisai, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Relmada, Sage, Shire, Sunovion, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Sunovion Pharmaceuticals Inc. Released: July 29, 2021 CME credit expires: July 29, 2024

How do you handle a patient who doesn’t want to talk about their suicidal thoughts? What tools and basic education strategies can we use for non-health-care professionals to highlight and prevent potential suicide/suicidal thoughts?  In this episode, Dr. Christine Moutier addressed your unanswered questions from the NEI Synapse Half Day: Before It’s Too Late: Strategies for Suicide Prevention. Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP).  Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide. Moutier has authored Suicide Prevention, a Stahl's series handbook, articles and book chapters for publications such as the Journal of the American Medical Association, the Lancet, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Depression and Anxiety, and Academic Psychiatry. She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets. You can follow Dr. Moutier on Twitter at @cmoutierMD. For more information on the AFSP please visit: asfp.org

How does the therapeutic alliance influence treatment outcomes when it comes to treatment with placebo? What are some of the other patient characteristics that influence placebo responsivity? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn about why understanding more about placebo and nocebo effects is so important for your practice. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg    https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

What are the most common mistakes in psychopharmacology, where clinicians could benefit from improvement in these areas? What are some ways in which clinicians can avoid malpractice lawsuits? In this podcast episode, Dr. Thomas Schwartz discusses the biggest mistakes that can be made in psychopharmacology, as well as best practices for clinicians to avoid malpractice in psychiatry. You won’t want to miss this episode! Dr. Thomas L. Schwartz is a professor and the Interim Chair for the Department of Psychiatry and Behavioral Sciences, and Senior Associate Dean for Education at SUNY Upstate Medical University, Syracuse, NY. He is active on many teaching, administrative and curriculum committees at SUNY, he also provides direct resident supervision, lectures in several courses, and directs and organizes continuing medical education events for the psychiatry department. Dr. Schwartz received his medical degree from and completed his residency in adult psychiatry at the State University of New York (SUNY) Upstate Medical University in Syracuse, New York. Dr. Schwartz’s abilities as a medical educator have been recognized with the Marc H. Hollander, MD, Psychiatry Award, Teacher of the Year, and Mentor of the Year awards from SUNY Upstate Medical University; Nancy Roeske, MD, Irma Bland, Certificates of Recognition for Excellence in Medical Student and Resident Education from the American Psychiatric Association, the SUNY Upstate President’s and the SUNY Chancellor’s Award for Teaching. Dr. Schwartz is the author of Practical Psychopharmacology: Basic to Advanced Principles, "Stahl’s Essential Psychopharmacology” Case Studies Volume 2, Integrating Psychotherapy and Pharmacotherapy, Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, Second and Third Generation Antipsychotics. He is the editor of Depression: Treatment Strategies and Management, 1st and 2nd Eds. and is the Deputy Editor for the journal CNS Spectrums.

What do we know about the world suicide rate and the national suicide rate? What are the differences and how might they be explained? How does the role of medications help or hinder suicide prevention? In this episode, Dr. Andrew Cutler interviews Dr. Christine Moutier and Dr. Stephen Stahl on their Suicide Prevention Handbook, where they address timely questions like these and so much more. Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP).  Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide. Moutier has authored Suicide Prevention, a Stahl's series handbook, articles and book chapters for publications such as the Journal of the American Medical Association, the Lancet, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Depression and Anxiety, and Academic Psychiatry. She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets. You can follow Dr. Moutier on Twitter at @cmoutierMD. For more information on the AFSP please visit: asfp.org With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are the positive and negative consequences surrounding self-diagnosis programs for mental health? What can you say about the trend on TikTok to take L-tyrosine? It’s apparently been nicknamed the “natural Adderall”. What is wrong with this, or potentially dangerous about this? In this episode, Dr. Kojo Sarfo, discusses the positive and negative consequences of the mental health trends on TikTok and social media. Dr. Kojo Sarfo, DNP, PMHNP-BC is a Ghanaian-American Psychiatric-Mental Health Nurse Practitioner, entrepreneur, and writer. He graduated from The University of West Alabama with his Associate’s Degree in Nursing and then obtained his Bachelor’s in Nursing from Western Governors University. He went on to obtain his Doctorate in Nursing Practice degree from Augusta University with a specialty in Psychiatry. Dr. Sarfo is dedicated to increasing awareness about mental health conditions and reducing the stigma that surrounds mental health on social media platforms, such as TikTok. His mission has been received with growing popularity, particularly in the adolescent/youth community- as he has over one million followers on TikTok. He has three years of teaching experience as an adjunct faculty professor with the College of Nursing at his alma mater, Augusta University. He has a passion for treating and caring for persons with severe mental health conditions. He is also the CEO and Co-Founder of Abrantie & Signora, LLC, which is a clothing company dedicated to spreading positivity and mental health awareness for teenagers and college students. For more information on Dr. Sarfo: https://www.kojosarfo.com/ Dr. Sarfo’s Podcast: https://podcasts.apple.com/us/podcast/the-kojo-sarfo-podcast/id1477749374 Dr. Sarfo’s YouTube Channel: https://www.youtube.com/kojosarfo Dr. Sarfo’s Clothing Company: https://abrantiesignora.com/ Dr. Sarfo’s Book: https://www.amazon.com/You-Already-Won-Education-Awareness/dp/1692141805/ref=sr_1_1?dchild=1&keywords=dr.+kojo+sarfo&qid=1603218480&sr=8-1

What are the most frequent comorbidities of schizophrenia? Is there any scientific reason to use any antipsychotic in twice-a-day dosing? In this episode, Dr. Leslie Citrome addresses these questions and more of your unanswered questions from the NEI Synapse Half-Day on Novel Strategies to Treat Schizophrenia in this special NEI Podcast Bonus episode! Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation. Dr. Citrome is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Main areas of interest include schizophrenia, bipolar disorder and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm. Dr. Citrome is the author or co-author of over 400 research reports, reviews, and chapters in the scientific literature, is on the editorial board of 13 different medical journals, reviews for over 90 journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.

What unique risk factors surround the COVID-19 pandemic and potential heightened risk of suicide? What populations have been most vulnerable to mental health consequences, substance use disorders, suicidal ideation, and self-harm during the pandemic and why? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on the suicide risk and prevalence during this challenging time. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are some mental health challenges for Asian Americans today? Can you share your thoughts on the most recent acts of violence against Asian Americans and where it comes from? In this timely and important episode, we interview Dr. Rona Hu on mental health in the Asian American community. Dr. Hu is Medical Director of the Acute Psychiatric Inpatient Unit at Stanford Hospital, specializing in the care of those with serious mental illnesses, including schizophrenia, bipolar and depression. She completed medical school and residency in psychiatry at the University of California, San Francisco, and fellowships in Pharmacology and Schizophrenia Research through the National Institutes of Health. She is also active in  minority issues and cultural psychiatry, and has received regional and national recognition for her clinical care, research and teaching. Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology. Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998. Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.

What is the evidence that obesity leaves one vulnerable to bipolar disorder? Which of your patients with bipolar disorder would you refer for TMS and what has been the outcome in your experience? Have you seen development of mania with this treatment? What impact or changes have you seen in your bipolar patients who have suffered with COVID? In this Bonus episode of the NEI Podcast, Dr. Roger McIntyre addresses these questions and more unanswered questions from the Q&A session for our NEI Synapse Half-Day on The Cutting-Edge of Mood Disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders. To register for Synapse Half-Days go to: https://www.neiglobal.com/Synapse/SynOverview/tabid/468/Default.aspx

What do clinicians need to know about the pharmacokinetics of ketamine, especially when it comes to drug-drug interactions? What is the abuse potential for ketamine and for esketamine? What are some ways that clinicians can mitigate the risk of abuse? At this time, what is the consensus, in comparing the efficacy of ketamine and esketamine for treatment resistant depression? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on their recent publication in the American Journal of Psychiatry. To access the article click on the link: https://pubmed.ncbi.nlm.nih.gov/33726522/ Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

What has the research shown in terms of the relationship between THC and sleep and nightmares in patients with PTSD? What are your thoughts on the recent study by LaFrance et al. that claimed that PTSD symptoms were reduced by more than 50% after cannabis use? In this fascinating interview with Dr. Kari Franson, we discuss the evidence for and against the use of cannabis to treat PTSD. Kari L. Franson PharmD, PhD, BCPP joined the University of Southern California in 2020 as the Associate Dean for Academic and Student Affairs and Professor of Clinical Pharmacy. Dr. Franson received her Doctor of Pharmacy from the University of California, San Francisco, trained at the University of Illinois, Chicago Hospital and Clinics as a resident in adult internal medicine and a fellow in clinical research/drug development, and received her PhD in Medical Education from Leiden University, the Netherlands. Dr. Franson is an educator with more than 25 years of experience. Throughout her career, she has focused on two areas: health professions education/workforce development and psychopharmacology. She is an international leader in interprofessional practice, education and advocacy and workforce development to address health disparities in both the US and abroad. Dr. Franson has experience in campus and distance-based curriculum development and assessment, technology-enhanced assessment/learning, experiential education, and continuing professional education and development. Dr. Franson is also a US Board-Certified Psychiatric Pharmacist and Dutch-Certified Clinical Pharmacologist. She worked with geriatric psychiatric patients for 10 years and has performed a variety of clinical studies spanning those in early-phase clinical pharmacology to post-marketing clinical efficacy studies. She is interested in cannabinoid clinical pharmacologic effects and cannabis user safety. She has guided national and international professional, legislative, media and commercial groups on the wise study and use of cannabis.  

What exactly is reconsolidation? How does disrupting this process work to neutralize fear conditioning? How has hallucinogen-assisted psychotherapy been implemented as an attempt to block reconsolidation of activated memories during psychotherapy sessions In this episode, as part of our special series, the PsychopharmaStahlogy Show, Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part 3 of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part 1: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part 2: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part 3: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are the risk factors for pediatric anxiety, and how might those be altered by the pandemic? How can emotional intelligence and emotion regulation play a role in managing anxiety? What is self-efficacy, and why is it so important for managing pediatric anxiety? In this timely episode, we discuss how to manage pediatric anxiety with Dr. Krystal Lewis. Dr. Lewis is clinical psychologist with the Section on Development and Affective Neuroscience (SDAN) at the National Institute of Mental Health (NIMH). She is also a member of the Stigma Scientific Interest Group (SIG), and the NIMH Anti-Racism Task Force at the National Institute of Health (NIH). She specializes in cognitive behavioral therapy (CBT) for treating pediatric anxiety, and her research has focused on identifying mechanisms underlying the effectiveness of CBT. Dr. Lewis has extensive clinical experience treating anxious children and adolescents. She is also an advocate for early intervention, prevention and evidence-based treatments. She is currently a member of the Board for the Anxiety and Depression Association of America and co-chairs the Child and Adolescent Anxiety Special Interest Group. Resources Research Involvement at the NIMH: www.nimh.nih.gov/research Clinical Studies at the NIMH: clinicalstudies.info.nih.gov Clinical Study on Pediatric Anxiety: https://www.nimh.nih.gov/research/research-conducted-at-nimh/join-a-study/trials/childrens-studies/pediatric-mood-and-anxiety-research.shtml Call: (301) 827-1340 /Email: [email protected] Websites My Mental Health: Do I Need Help? (NIMH) 5 Things You Should Know About Stress (NIMH) COVID-19: Stress and Coping (CDC) Anxiety and Depression Association of America: https://adaa.org/ Books for children/adolescents Outsmarting Worry: The Older Kids’ Guide to Managing Anxiety: https://www.amazon.com/Outsmarting-Worry-Older-Managing-Anxiety/dp/1785927825/ref=sr_1_1?dchild=1&keywords=outsmarting+worry&qid=1613673934&s=books&sr=1-1 Rewire Your Anxious Brain For Teens: https://www.amazon.com/Rewire-Your-Anxious-Brain-Teens/dp/1684033764/ref=sr_1_3?dchild=1&keywords=rewire+your+anxious+brain+for+teens&qid=1613674062&s=books&sr=1-3 https://www.amazon.com/Teen-Girls-Anxiety-Survival-Guide/dp/1684035848/ref=sr_1_3?dchild=1&keywords=the+teens+girls+anxiety+survival+guide&qid=1613677471&s=books&sr=1-3#customerReviews Books for Parents : https://www.amazon.com/Helping-Anxious-Child-Step-Step/dp/1572245751/ref=sr_1_1?dchild=1&keywords=helping+your+anxious+child&qid=1613674245&s=books&sr=1-1 https://www.amazon.com/You-Your-Anxious-Child-Worries/dp/1583334955/ref=sr_1_1?dchild=1&keywords=anne+marie+albano&qid=1613677395&s=books&sr=1-1 https://www.amazon.com/Anxious-Kids-Parents-Courageous-Independent/dp/0757317626/ref=sr_1_3?crid=VR7NZWB285S2&dchild=1&keywords=anxious+parents+anxious+kids&qid=1613677372&s=books&sprefix=anxious+parents+%2Cstripbooks%2C167&sr=1-3

What has research shown about the effectiveness of psychedelic or dissociative agents in the treatment of addiction? What is pharmacological extinction? What types of addictions have been researched, using this method as a treatment approach? In Part II of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part III: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories Subscribe to the NEI Podcast, so that you don’t miss another episode!

What are the greatest mental health disparities in this population? What has been particularly challenging for the transgender population during the COVID-19 pandemic? How can clinicians help recognize and treat the mental health needs of patients in the LGBTQ community, if they do not have advanced or specialized training for this population? In this double-interview we had the opportunity to sit down with two experts who address these questions, and so much more! Dr. Rhonda Schwindt is an Associate Professor and Director of the Psychiatric-Mental Health Nurse Practitioner Program at The George Washington University School of Nursing. She is a nationally certified Psychiatric-Mental Health Nurse Practitioner with an active clinical practice specializing in LBGTQ health, trauma, and treatment-resistant psychiatric illnesses. Dr. Schwindt’s research is focused on reducing the disproportionate impact of substance use disorders among high risk populations. She has developed an innovative online module that prepares clinicians to engage in motivational interviewing and a web-based tool to assist busy clinicians with screening and brief intervention. Dr. Schwindt is currently conducting a study exploring the barriers to, and facilitators of, smoking cessation and treatment utilization among gender diverse people. She has received international recognition as an outstanding nurse educator as well as for clinical excellence in the care of persons living with mental illness.  Dr. Stephen Forssell is the founder, director, and professor of the LGBT Health Policy & Practice Graduate Certificate Program at the George Washington University. In addition, he has been an assistant professor in the Psychological and Brain Sciences Department at the George Washington University since 2002 where he teaches courses in sexuality and gender, health psychology, and social psychology. He is on the faculty of the GWU Medical Center School of Medicine and Health Sciences course in Human Sexuality and Clinical Medicine. Dr. Forssell’s expertise is in sexual orientation development, same-sex romantic relationships and parenting, HIV/AIDS risk behaviors, high risk sexual behavior interventions, adolescent and young adult romantic and sexual relationships, and health psychology. Dr. Forssell also designs program evaluations for the Human Services Administration, the Substance Abuse and Mental Health Services Administration, and for private agencies including the National Minority AIDS Council and the AIDS Alliance.  Resources: LGBT Health Policy & Practice Graduate Certificate Program at the George Washington University: https://lgbt.columbian.gwu.edu/ National LGBTQIA Health Education Center:  https://www.lgbtqiahealtheducation.org/ Human Rights Campaign: https://www.hrc.org/

What types of psychotherapies are typically used in conjunction with these dissociative agents? How does psilocybin differ from ketamine for the treatment of mental health conditions? What are the risks, if any associated with this type of therapeutic approach? In Part I of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part II and Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part III: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this excerpt, taken from his  presentation on the mental health consequences of COVID-19 for 2020NEIMax!, Dr. Sauve' addresses the rise in substance use disorders, and domestic violence as a result of the 2020 pandemic.  Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines. After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Regional Medical Director, Virginia; Greenbrook TMS NeuroHealth Centers and the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well. He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.

We know that the COVID-19 pandemic has had a significant impact on mental health around the world. Can you share some findings with us on the effect of COVID-19 on mood disorders from the CLIMB study that was conducted this year? What were some of the new FDA approvals for medications that happened this year? In this episode, Dr, Cutler addresses these questions and so much more, as we take a look back at this year in psychopharmacology. Dr. Andrew J. Cutler is Chief Medical Officer at the Neuroscience Education Institute, and Clinical Professor in the Department of Psychiatry at SUNY Upstate Medical University, Syracuse, NY Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials. He has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards. He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations. He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences. Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association. He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media.  

Neurodegenerative disorders have become increasingly prevalent today and can often be accompanied by dementia and other neuropsychiatric conditions such as psychosis. It is important to be able to differentiate psychosis that is associated with various types of dementia, while this can be challenging to clinicians. However, there are several existing and novel therapeutics that can manage dementia-related psychosis. In this episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo on the practical strategies for the management of dementia-related psychosis. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-DemPsychosis Learning Objectives: After completing this educational activity, you should be better able to: Describe the clinical presentation of psychosis in dementia Employ pharmacological treatment strategies to ameliorate psychosis in patients with dementia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by a PhD specializing in neurodegenerative diseases to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Laxman Bhagwan Bahroo, DO Associate Professor and Residency Program Director, Department of Neurology; Director, Botulinum Toxin Clinic; MedStar Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC Consultant/Advisor: AbbVie, Acadia, Acorda, Allergan, Amneal, Neurocrine, Revance, Sunovion, US World Meds Speakers Bureau: AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal, Ipsen, Neurocrine, Sunovion, UCB, US World Meds Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Acadia Pharmaceuticals. Released: December 14, 2020     CME credit expires: December 14, 2023

Despite increasing evidence that bipolar disorders often emerge in adolescence, only about half of adolescents with a bipolar disorder receive mental health care. Research has shown that an early onset of a bipolar disorder, concomitant with a poor diagnosis and lack of treatment, can have lifelong devastating effects for the patient. Adults and younger people who initially exhibit symptoms only of depression may later develop bipolar disorder. The risk of depression turning into bipolar disorder is estimated at 10 percent or less in adults but appears to be as high as 20–40 percent in children and adolescents. In this episode, Dr. Neera Ghaziuddin answers many questions regarding how to better diagnosis and treat pediatric bipolar disorder, and depression with mixed features in the pediatric population. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-PedBip Learning Objectives: After completing this educational activity, you should be better able to: Discuss challenges to diagnosing bipolar disorder in the pediatric population (e.g. adolescents) Define the concept of “mixed features” according to different diagnostic criteria Improve the differential diagnosis of depression with mixed features (DMX) in children and adolescents Utilize evidence-based therapies in the treatment of pediatric patients presenting with DMX Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in pediatric psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Neera Ghaziuddin, MD, MRCPsych Professor, Child and Adolescent Psychiatry Unit, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found at https://nei.global/culture. Support: This activity is supported by an unrestricted educational grant from Sunovion. Released: December 3, 2020     CME credit expires: December 3, 2023

How can someone tell whether they are experiencing chronic levels of stress? The holidays are typically a great source of stress for most people. What are the unique challenges that we face this year in terms of the holidays during a pandemic? In this timely interview, Dr. Jennifer Love addresses these important questions, and so much more in this episode. With the release of her upcoming book, “When Crisis Strikes” she shares some powerful tips on detecting and managing chronic stress. Dr. Jennifer Love is board-certified in psychiatry, addiction psychiatry and addiction medicine, and is a Diplomate of the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She practices at a large clinic in Southern California. Dr. Love is an award-winning researcher and international speaker, interested in the interface between cultural and spiritual factors and overall mental health. Dr. Love’s work focuses on restoring life balance, brain and body health, and helping her patients improve their functionality and satisfaction in life. She considers a wide range of interventions including nutraceuticals, medication, exercise, yoga, psychotherapy, and sleep/relaxation training. Her specialties include: mood disorders, substance-use disorders, anxiety disorders, anger and irritability, behavioral addictions, co-occurring pain and opioid dependence. Dr. Love is the co-author of When Crisis Strikes: 5 Steps to Heal Your Brain, Body, and Life from Chronic Stress. Stay up to date by following @dr_author_jennifer_love on Instagram.        

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements of the tongue, lips, face, trunk, and extremities that occur in patients treated with dopamine receptor blocking agents (DRBAs). Patients can have symptoms that persist for months, years, or even permanently. Greater awareness about risk factors and which agents may be associated with higher likelihood of developing TD is critical to reduce the prevalence of this disorder. Understanding the most effective novel treatment approaches to TD is also important. In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the current best practices in the diagnosis, recognition, and treatment of tardive dyskinesia.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-TD  Learning Objectives: After completing this educational activity, you should be better able to: Identify the clinical presentation of tardive dyskinesia Implement treatment strategies for the management of tardive dyskinesia  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by a PhD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Neurocrine Continental, Inc.  Released: November 19, 2020          CME credit expires: November19, 2023

What are the most common reasons for insomnia? What is effective for treating insomnia? Can you explain sleep hygiene? In Part 2 she answers these questions and so much more! Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post. Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives.  My website: www.JadeWuPhD.com Twitter: @JadeWuPhD Resources can be found on her website under the "Resources" tab.

Join us for this important extended Q&A session with psychiatric nurse practitioner; Deb York, in which she answers your most pressing questions from her presentation on early life childhood adversity.

Join us for a fascinating extended Q&A with Dr. William Sauve’ where he addresses your unanswered questions from his presentation on the mental health consequences of COVID-19.

In this episode, listen in for an extended Q&A session with Dr. Jeffrey Strawn as he answers your most pressing questions from his presentation on treating refractory anxiety disorders.

In this exciting extended Q&A session, Dr. James Knoll addresses your unanswered questions from his presentation on Mass Shootings.

How do we know how much sleep we actually need? Are devices like the FitBit accurate at tracking what stage of sleep we’re in, according to heart rate? How does substance abuse contribute to nightmares? In this episode of the NEI Podcast, psychiatrist and sleep researcher, Dr. Jade Wu answers these questions and so much more! Learn about her cutting-edge research in Part 1 of this episode. Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post. Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives.  My website: www.JadeWuPhD.com Twitter: @JadeWuPhD Resources can be found on her website under the "Resources" tab.

How are social media platforms being used for negativity and what can people do to protect their mental health on these platforms? How have you used Tiktok and other social media platforms to help remove the stigma associated with mental health conditions, and to make a positive impact in the adolescent population? In this episode, we interview psychiatric nurse practitioner, Dr. Sarfo Kojo on how he is using social media to create a positive impact on mental health. Dr. Kojo Sarfo, DNP, PMHNP-BC is a Ghanaian-American Psychiatric-Mental Health Nurse Practitioner, entrepreneur, and writer. He graduated from The University of West Alabama with his Associate’s Degree in Nursing and then obtained his Bachelor’s in Nursing from Western Governors University. He went on to obtain his Doctorate in Nursing Practice degree from Augusta University with a specialty in Psychiatry. He has three years of teaching experience as an adjunct faculty professor with the College of Nursing at his alma mater, Augusta University. He has a passion for treating and caring for persons with severe mental health conditions. He is also the CEO and Co-Founder of Abrantie & Signora, LLC, which is a clothing company dedicated to spreading positivity and mental health awareness for teenagers and college students. Dr. Sarfo has over 328,000 followers on TikTok. For more information on Dr. Sarfo: https://www.kojosarfo.com/ Dr. Sarfo’s Podcast: https://podcasts.apple.com/us/podcast/the-kojo-sarfo-podcast/id1477749374 Dr. Sarfo’s YouTube Channel: https://www.youtube.com/kojosarfo Dr. Sarfo’s Clothing Company: https://abrantiesignora.com/ Dr. Sarfo’s Book: https://www.amazon.com/You-Already-Won-Education-Awareness/dp/1692141805/ref=sr_1_1?dchild=1&keywords=dr.+kojo+sarfo&qid=1603218480&sr=8-1  

What is an ecological momentary assessment? How are ecological momentary interventions powerful and helpful in a clinical research setting? Learn more about how digital technology, smart phone applications, electronic surveys, and wearable devices can help in both the clinical research and the clinical treatment arena. In this fascinating interview with Dr. Katherine Houghton, she answers your most pressing questions about applying digital technology to capture real-world/real-time data, and to help patients at the most critical times. Katherine Houghton, Ph.D. is fascinated by the intersection of technology and psychology. She is actively engaged in designing and testing systems to facilitate positive behavior change in a variety of populations. She co-founded ilumivu in 2009 (ilumivu.com) to provide software systems to researchers and clinicians to capture human data and deliver just-in-time interventions. Ilumivu's first software service was for parents of children with autism to track symptom change and treatment use in an online HIPAA compliant, sharable platform. Since then ilumivu has provided web, mobile and wearable systems to researchers and clinicians working with a wide range of populations including substance abuse, suicide, anxiety and depression. They are committed to finding innovative and effective ways to use everyday technology to improve the daily life experience of the millions of people who suffer with mental health issues. *Optional*Kat is also very engaged in local environmental activism bringing Community Rights and the Rights of Nature to the City of Asheville through a nonprofit she co-founded, Community Roots (cmroots.com). She also leads wilderness Rites of Passage ceremonies to help people through challenging times. Resources: Ilumivu website: https://ilumivu.com/ Ilumivu Twitter: https://twitter.com/ilumivuTweets Kat's LinkedIn: https://www.linkedin.com/in/kathoughton/ Website to Kat's non-profit, Community Roots: https://www.cmroots.com/   Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.  

Opioid addiction, abuse, and overdose have all grown to epidemic proportions in the United States as well as worldwide in recent years—such information is no longer up for debate. With an estimated 400,000 persons using illicit opiates each month, and another 4 million reporting use of prescription pain relievers for nonmedical purposes, in the United States alone, the debate now surrounds how best to treat those individuals suffering from opioid use disorder (OUD). In the past few years, there has been growing evidence for the efficacy of medication assisted therapy (MAT) for the treatment of OUD. However, there are still many challenges. Questions arise such as: What sort of training does a prescriber need to undertake in order to be able to prescribe medications for the treatment of OUD and how is this a barrier to treatment? How are the billing procedures for MAT challenging for clinicians who are prescribing? In this CME NEI Podcast, Dr. Larissa Mooney answers these questions and more on MAT for OUD. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges to treating opioid use disorder (OUD) with medication assisted therapy (MAT) Explore treatments designed to optimize cessation of opioid addiction Discuss legal barriers and insurance barriers to treatment of OUD  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as “providers of formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Faculty Interviewer / Author Larissa J. Mooney, MD Associate Clinical Professor, Department of Psychiatry and Biobehavioral Sciences; Director, Addiction Medicine Clinic; University of California, Los Angeles Semel Institute for Neuroscience and Human Behavior, Los Angeles, CAChief, Substance Use Disorders Clinic, VA Greater Los Angeles Healthcare System, Los Angeles, CA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Alkermes.  Released: Sept 30, 2020          CME credit expires: Sept 30, 2023   Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.

September is National Recovery Month! In this invigorating interview with addiction expert, Dr. Nzinga Harrison, we discuss the need for removing the stigma and misconceptions surrounding the topic of addiction, and how to apply treatment strategies focused on understanding compassion, and evidence-based scientific research. When it comes to addiction, there are many questions. What does it mean to say that someone is in recovery? What are some behavioral addictions that most people don’t think about? Are there such things as healthy addictions? In this episode, Dr. Harrison shares a refreshing and novel perspective on the topics of addiction and recovery. A well-respected physician and educator, Dr. Harrison is the host of the In Recovery weekly podcast by Lemonada Media, she engages a large audience on all things addiction with the goal of leading with compassion, evidence and reducing stigma.   She is Chief Medical Officer and Co-Founder of  Eleanor Health, an innovative company who provides comprehensive, longitudinal outpatient care for individuals experiencing opioid and other substance use disorders. She earned her Bachelor’s degree in Biology with Spanish and Chemistry minors at Howard University, completed medical school at the University of Pennsylvania School of Medicine and General Psychiatry Residency at Emory University.   She is Board-Certified in both Adult General Psychiatry and Addiction Medicine and has spent her career treating individuals with Serious Persistent Mental Illness and Addictive Diseases.  Currently, she holds adjunct faculty appointments at the Morehouse School of Medicine Department of Psychiatry is Co-Founder of Physicians for Criminal Justice Reform, Inc. and Campaign Psychiatrist for Let’s Get Mentally Fit, a public education and stigma-reduction campaign.   Resources: Dr. Nzinga Harrison’s In Recovery Podcast: https://www.lemonadamedia.com/show/in-recovery/ Eleanor Health: https://www.eleanorhealth.com/  

When it comes to serious mental illness (SMI), mental health professionals work hard to help remove the associated negative stigma, and to educate patients and caregivers to help them thrive. In this episode, we interview two clinical experts who are part of an interdisciplinary team at the APA/SMI Advisor program. This joint initiative between the American Psychiatric Association and the Substance Abuse and Mental Health Services Administration, or SAMSHA is an innovative clinical support program for clinicians, caregivers, and patients with serious mental illness.  In this episode, we discuss the topic of serious mental illness with two mental health experts, Dr. Donna Rolin and Dr. Joseph Ventura. We also discuss their upcoming joint-presentation at this year’s APNA, on the importance of incorporating the Basic Psychiatric Rating Scale (BPRS) into practice.   Donna Rolin, Ph.D. is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing. She is co-leading inter-disciplinary graduate training initiatives with Schools of Nursing, Medicine, Educational Psychology, Social Work, and Pharmacy with funding from the Health Resources and Services Administration and the Texas Higher Education Coordinating Board aiming to expand a culturally diverse workforce for underserved populations. She serves as the Co-Director of the Institute for Domestic Violence and Sexual Assault (IDVSA), working alongside Schools of Social Work, Law and Bureau of Business Research. Dr. Rolin’s current research focuses on wellness self-management for mental health promotion and the integration of telepresence robots in healthcare education. Dr. Rolin serves on the national Board of Directors of the American Psychiatric Nurses Association and the local Board of the Directors of the Psychiatric Advanced Practice Nurses of Austin. Dr. Rolin continues her clinical practice as a Psychiatric Advanced Practice Registered Nurse with a community-based group working with underserved patients with serious mental illnesses (SMI), neurocognitive disorders, and intellectual disabilities in outpatient, long term care, telepsychiatry, and inpatient psychiatric facilities. She acts as the SMI Nursing Expert on the American Psychiatric Association’s Clinical Support Services for SMI (CSS-SMI) Clinical Expert Team. Joseph Ventura, Ph.D. is a Clinical Psychologist and Research Scientist with expertise in the assessment and treatment of individuals with serious mental illness. Dr. Ventura is the Director of Cognitive Training and Diagnosis and Symptom Assessment for the UCLA Aftercare Program. His areas of expertise include cognitive remediation, assessment of neurocognitive functioning, psychiatric diagnosis, symptom assessment, recovery from mental illness, and evaluation of functional outcomes in the early phase of schizophrenia. Dr. Ventura has led research funded by several agencies most notably the National Institute of Mental Health (NIMH) and the Brain and Behavior Foundation (formerly NARSAD). His research has concentrated on stressful life events, positive and negative symptoms, neurocognition, social cognition, cognitive training, and predictors of course and functional outcome. Dr. Ventura has played a major role in the development and publication of methods for standardizing diagnostic and symptom assessment training and for ongoing quality assurance. His recent work focuses on clinical correlates of the core features of serious mental illness, dimensions of social cognition, inflammatory biomarkers, the development of interview-based assessments of cognitive functioning, and factors that are associated with recovery from serious mental illness. Recently, he was awarded a US Fulbright Scholar Grant to develop a program promoting early assessment, identification, and prevention of mental illness in clinical high-risk populations in North Africa. Dr. Ventura has published widely in peer-reviewed journals, lectured extensively, and conducted numerous training workshops both nationally and internationally. UCLA Aftercare Program: The UCLA Aftercare Program (brochure attached) is a joint clinical and research program located in the UCLA Department of Psychiatry specializing in the treatment of people who are in the early phase of schizophrenia or a related psychotic disorder. For over 30 years, and through NIMH and industry funding, our Aftercare treatment team has been providing comprehensive services to schizophrenia patients most of whom are transitional age youth (late teens or early twenties). However, we can serve patients from age 18 to 45. Our primary treatment aim is to assist patients with symptomatic and functional recovery after experiencing a first psychotic episode or who are within 2 years of the first onset of psychotic symptoms.  The Aftercare program provides a comprehensive set of treatment services to eligible patients including regular visits with a psychiatrist, anti-psychotic medication (second generation), case management, various forms of psychosocial interventions including group and individual therapy, a cognitive training program that is in some cases boosted by an aerobic exercise program, family education and support, and transportation to UCLA. Our clinic psychiatrists are Laurie Casaus, M.D. and Margaret Distler, M.D. Additional Aftercare services include, supported employment and supported education programs, family therapy, and providing research updates to family members. We can provide all of these services for up to two years at no cost to the patient or family because we are funded.   The Aftercare clinic is headed by members of the UCLA Department of Psychiatry, Keith Nuechterlein, Ph.D., Kenneth Subotnik, Ph.D., Luana Turner, PsyD., Joseph Ventura, Ph.D, who have been providing these services through the Aftercare Program for many years to early course patients. Rebecca Zornitsky, MSc. is our Community Liaison Specialist along with Taylor Jester and Elaine Clarke. APA/SMI Adviser Site & Resources: https://smiadviser.org/ Clozapine Center of Excellence: https://smiadviser.org/about/clozapine Long-Acting Injectable (LAI) Antipsychotics Center of Excellence: https://smiadviser.org/about/lai How to download SMI Adviser App: Apple: https://apps.apple.com/us/app/smi-adviser/id1473024646 Google: https://play.google.com/store/apps/details?id=org.smiadviser&hl=es_PE How to download My Mental Health Crisis Plan (Psychiatric Advance Directive [PAD]) App Apple: https://apps.apple.com/us/app/my-mental-health-crisis-plan/id1497373282 Google: https://play.google.com/store/apps/details?id=org.smiadviser.apa&hl=en_US APNA Annual Meeting Presentation on Brief Psychiatric Rating Scale (BPRS) Annual Meeting 9/30 – 10/4/2020 (Virtual) https://www.apna.org/i4a/pages/index.cfm?pageid=3467 Presentation on BPRS – Dr. Joseph Ventura & Dr. Donna Rolin Thursday, 10/1 @5pm ET https://www.apna.org/i4a/pages/index.cfm?pageID=4595 2034: Advanced Practice 5:00pm ET - 5:45pm ET Using the Brief Psychiatric Rating Scale (BPRS) as a Symptom Assessment Tool in Measurement-Based Care – RN, APRN This interactive presentation teaches participants to rate psychiatric symptoms using a structured interview, the Brief Psychiatric Rating Scale. The goal is to build and/or expand assessment skills for rating initial symptom severity and for monitoring symptom change over time to improve quality of treatment within a measurement-based care approach.  Abstract Presenters: Joseph Ventura, PhD; Donna Rolin, PhD, APRN, PMHCNS-BC, PMHNP-BC  

Autism Spectrum Disorder (ASD) is highly comorbid with other psychiatric disorders, including attention deficit hyperactivity disorder (ADHD). Unfortunately, there may be many overlapping symptoms between ASD and ADHD that make it difficult to distinguish between these disorders. In this fascinating episode, Dr. David Goodman examines the history of autism, Asperger’s disorder, and how to differentiate between overlapping symptoms for ADHD. He also addresses how to treat these disorders concurrently. Dr. David W. Goodman is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology.

What specific issues do female nurse practitioners, or physicians treating mental health face in the workplace? What are some of the work-life issues that women face, when it comes to balancing a career in medicine with family? What are the research findings on sexual harassment toward women in the mental health profession? In this important episode, Dr. Christina Girgis addresses these questions, and more! Dr. Christina Girgis is a psychiatrist in the Hines, Illinois area, certified by both the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She is currently the Medical Director of the Consultation-Liaison Psychiatry Service at Edward Hines, Jr. VA Hospital and the Associate Training Director of the Psychiatry Residency Program at Loyola University Medical Center. She is also the founder of Psychiatry Network, and several other professional Facebook groups. For more information please click on the link below: https://www.facebook.com/groups/psychnetwork/

Schizophrenia is a chronic and debilitating disorder that creates a substantial burden not only for patients but also for their families. The high rates of treatment resistance, relapse rates, and incidence of adverse side effects in patients with schizophrenia suggest that a major treatment gap continues to exist. Given the high rates of treatment resistance, novel strategies and therapeutic approaches beyond D2 receptor blockade are being intensively studied. What are some of these novel approaches? How effective are they in the treatment of schizophrenia? What medications are available, or emerging that target neurotransmitters systems beyond dopamine? In this podcast episode, Dr. Jonathan Meyer and Dr. Leslie Citrome discuss some of the ground-breaking work in this field, and how you can better treat patients with schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe clinical advances in our understanding of schizophrenia Describe novel treatments for schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee / Author Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, Vanda Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Lilly, Johnson & Johnson, Merck, Pfizer Interviewee / Author Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies. Released: July 23, 2020          CME credit expires: July 23, 2023

What are some of the difficulties that Muslim Americans face today, and what was the reason behind the creation of the Muslim Wellness Foundation? How does stigma about mental health problems uniquely impact the Muslim American community? What are some of the psychosocial issues and challenges that Black Muslim American's experience?  In this important and timely episode, psychiatrist Dr. Mona Masood answers these questions and so much more! As a member of the Board of Directors at the Muslim Wellness Foundation, Dr. Masood offers resources, shares exciting programs and ways to get involved with this movement.    For more information on the Muslim Wellness Foundation click on the link below:  https://www.muslimwellness.com/  

The years 2019-2020 brought to us coronavirus disease 2019 (COVID-19), resulting in an unprecedented global pandemic. Emerging data, historical studies, and expert opinion point to a tremendous impact of COVID-19 on the development and exacerbation of psychiatric issues. This issue is compounded by the fact that access to mental health care services may be limited during this time of crisis. There is a critical need for mental health care providers to be prepared and educated to best serve the psychiatric needs of patients affected, either directly or indirectly, by the COVID-19 pandemic. There are still many questions. What are the psychological consequences of so many people losing their jobs, and so many businesses shutting down? What are some healthy coping strategies for parents to model at home, to protect their children’s mental health during this pandemic? In this CME NEI podcast episode, Dr. McIntyre answers these questions, and much more.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.  Learning Objectives: After completing this educational activity, you should be better able to: Discuss the psychological, economic, and sociological implications that COVID-19 has had on mental health Examine the impact of COVID-19 on a variety of mental health issues Explore existing and novel strategies for continuing mental health care during a global pandemic such as COVID-19 Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. Peer Review: The content was peer-reviewed by a PhD-PMHNP specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Faculty Interviewee / Author Roger S. McIntyre, MD, FRCPC   Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/Chinese National Natural Research Foundation, Stanley Medical Research Institute Consultant/Advisor: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Alkermes.  Released: July 9, 2020          CME credit expires: July 9, 2023  

What exactly is brain-derived neurotrophic factor, or BDNF? What is the relationship between neuroinflammation, BDNF, and depression? What are ways that we can naturally stimulate increases in BDNF? In this exciting interview, psychiatric nurse practitioner, Michelle Novella answers all these questions and more! Michele Novella, PMHNP-BC, PMHCNS-BC, is the owner and medical director of Star Psychiatric Healthcare, LLC, in Danbury, CT. She was educated at Fairfield University in Fairfield, CT, and received her Master's Degree in Adult Psychiatric Nursing from Yale University, graduating with high Honors. Additionally, Ms. Novella is an inductee into the Sigma Theta Tau International Honor Society and is an active member of the ANA, APNA, and CTAPRNS. She is also a past recipient of the American Cancer Society's prestigious "Excellence in Onocology" Nursing Award for the State of CT.  She is a national speaker for several pharmaceutical companies, including Takeda and Lundbeck.

Healthcare workers on the frontline, working to save patients with the COVID-19 virus, during this pandemic have been especially vulnerable to mental health consequences and trauma. In the early stages of the global shut-down, Dr. Mona Masood launched the Physician Support Line, a volunteer hotline to support physicians and healthcare providers who were on the frontlines, battling the virus, and the traumatic consequences of doing so, simultaneously. Doctors, nurses, EMTs and other health care workers have been under extremely stressful conditions, increased patient loads without necessary staffing, a lack of personal protective equipment (PPE), and overtime hours, placing them at high risk for contracting the virus themselves. Many have lost colleagues to the virus.  In this episode, learn what inspired her to create this hotline, what it has done for physicians, and how you can get involved. Dr. Mona Masood is board certified in general adult psychiatry and is an outpatient psychiatrist in the Ivyland, Pennsylvania area.  She is also the founder of the Physician Support Line and a Board Member of the nonprofit Muslim Wellness Foundation, which provides mental health educational services to the community. For more information on the Physician Support Line please go to: https://www.physiciansupportline.com/

Methamphetamine is an extremely serious problem in the United States, and it remains one of the most commonly misused stimulant drugs in the world. There are severe psychological, and medical consequences from methamphetamine misuse and abuse. This poses a particular challenge for clinicians treating patients for mental health conditions that are comorbid with substance use disorder (SUD). This is especially challenging when there are also interactions that can alter or influence psychiatric medications used to treat these patients. Questions such as the following arise: Given the high comorbidity of SUD with ADHD, how often should you check drug screens, and what is the threshold for discontinuing the stimulants if tests come back positive? In this podcast episode, Dr. William Sauve’ addresses these concerns, and much more. He also employs strategies to improve communication with patients about being transparent when it comes to using substances. Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Manage the challenges associated with psychiatric treatment of conditions comorbid with substance use disorder Integrate psychiatric drug interactions with methamphetamine use Assess treatments approaches for conditions associated with long-term use of methamphetamines Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer Andrew J. Cutler, MD   Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris   Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee William M. Sauvé, MD Regional Medical Director, Greenbrook TMS NeuroHealth Centers, Virginia Speakers Bureau: Avanir  Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported solely by the provider, NEI.  Released: June 8, 2020          CME credit expires: June 8, 2023

What is the prevalence of bipolar disorder in the pediatric population and does this change, depending on age? What are important tips for recognizing hypomania in children, and diagnosing children with mixed depression? In this episode, we address these questions and more with pediatric psychiatrist, Dr. Manpreet Singh.  Dr. Singh is Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders. She is the director of the Pediatric Mood Disorders Program and the Pediatric Emotion and Resilience Program at Stanford University. Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009. Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes. In her spare time, Dr. Singh enjoys traveling and hiking with her husband and three children, and avidly teaches Indian classical music. Her clinical handbook for the diagnosis and treatment of pediatric mood disorders can be found at the link below: https://appi.org/Products/Mood-Disorders/Clinical-Handbook-for-the-Diagnosis-and-Treatment?SearchText=clinical%20handboo&sku=37174

Healthcare disparities occur around the world, due to a complex, multifaceted situation that results from socioeconomic hardships, psychosocial stress, and cultural differences. In the United States, these disparities are often seen in minority communities, such as Hispanics and Black Americans. When a pandemic, such as COVID-19 occurs, it can expose these disparities in the most tragic ways. Current statistics surrounding healthcare disparities during the pandemic are staggering, suggesting that COVID-19 has disproportionately impacted the Black American community. In this important and timely interview with Dr. Napoleon Higgins, we address your most pressing questions on why this is occurring, and how awareness can improve this situation for future generations. Dr. Napoleon Higgins, Jr., is a psychiatrist in the Houston/Clear Lake City Area. He currently serves as Owner, CEO and President of Bay Pointe Behavioral Health Service, Inc., and South East Houston Research Group, Inc. He also practices as the Medical Director of Hold My Hand Residential Treatment Center. Dr. Higgins specializes in treating mental health disorders through medication management, psychotherapy and behavioral training.

Food and beverages interact with certain psychiatric medications to alter their pharmacokinetic properties, resulting in potentially unintended health outcomes. In this podcast episode, Dr. Rajnish Mago describes common food and beverages that interact with psychiatric medication and provides recommendations for avoiding unintended food-drug interactions. Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.  Learning Objectives: After completing this educational activity, you should be better able to: Describe the effects of food on the bioavailability of certain psychotropic medications Discuss current evidence of the brain-gut connection’s impact on mental health Describe the effects of vitamin C, caffeine, and grapefruit on the pharmacokinetics of certain psychotropic medications  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by a PharmD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer / Author Andrew J. Cutler, MD   Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris   Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee / Author Rajnish Mago, MD Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Travel Expenses: Intas Pharmaceuticals (for Indian Psychiatric Association annual meeting) Stockholder: Johnson and Johnson  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported solely by the provider, NEI.  Released: May 11, 2020          CME credit expires: May 11, 2023    

With the recent COVID-19 pandemic, mental health concerns are on the rise. What do we know about the relationship between suicide risk and previous pandemics or natural disasters? How do we distinguish between behavior that seems like appropriate coping during this time and behavior that should raise a red flag? What are some protective factors against suicide, and how can we capitalize on these, especially during this challenging time?  Join us, as we interview the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP), Dr. Christine Moutier. Dr. Moutier knows the impact of suicide firsthand. After losing colleagues to suicide, she dedicated herself to fighting this leading cause of death. Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide. Moutier has authored articles and book chapters for publications such as the Journal of the American Medical Association, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Psychiatric Times, Depression and Anxiety, and Academic Psychiatry. She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets. You can follow Dr. Moutier on Twitter at @cmoutierMD. For more information on the AFSP please visit: afsp.org

What is the evidence that exercise is at least as effective as medications for the treatment of mental health disorders, such as depression? Can you share any research findings on the effects of exercise for patients with traumatic brain injury?  If you have questions like these, you won't want to miss this episode with psychiatrist and renowed author, Dr. John Ratey! Best selling author, John J. Ratey, MD, is an Associate Clinical Professor of Psychiatry at Harvard Medical School and an internationally recognized expert in Neuropsychiatry. He has published over 60 peer-reviewed articles, and 11 books published in 17 languages, including the groundbreaking ADD-ADHD “Driven to Distraction” series with Ned Hallowell, MD. With the publication of  "Spark-The Revolutionary New Science of Exercise and the Brain," Dr. Ratey has established himself as one of the world's foremost authorities on the brain-fitness connection.  His most recent book, “Go Wild” explores how we can achieve optimal physical and mental health by getting in touch with our caveman roots, and how we can “re-wild” our lives.   Recognized by his peers as one of the Best Doctors in America since 1997, Dr. Ratey was recently honored by the Massachusetts Psychiatric Society as "Outstanding Psychiatrist of the Year" for advancing the field. Dr. Ratey and his work are frequently profiled in the media, where he’s been featured on ABC, CBS, NBC, PBS and NPR, as well as in The New York Times, Newsweek, The Washington Post, US News and World Report, Men’s Health, and other national publications.

Given the recent COVID-19 virus pandemic, how is pediatric anxiety influenced by things like the media, parental attitudes, and the family environment? How effective is telepsychiatry for pediatric patients? If you have these types of questions you won't want to miss this timely and important interview with psychiatrist Dr. Jeffrey Strawn! In this episode, we discuss issues like effective communication strategies for parents during this time, and how to best meet the needs of pediatric patients with anxiety. Dr. Strawn is an Associate Professor of Psychiatry and Pediatrics at the University of Cincinnati and at Cincinnati Children’s Hospital. He directs the University of Cincinnati Anxiety Disorders Research Program. His ongoing research explores the pathophysiology and psychopharmacology of anxiety disorders, using functional neuroimaging and magnetic resonance spectroscopy. His research further aims to identify early predictors of treatment response in anxiety and to identify which patients may respond best to which specific treatments. In his clinical practice, he works with youth with anxiety disorders and with their parents and families. 

What is our current understanding of the gut-brain connection? What is the difference between the microbiome and microbiota? How is dysbyosis of the gut associated with certain psychiatric disorders? In this CME podcast, we address these questions and more in this captivating interview between Dr. Andrew J. Cutler and Dr. Roger S. McIntyre! Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Explore the relationship between the brain-gut-microbiome axis and chronic inflammation Discuss current evidence of the brain-gut connection’s impact on mental health Consider potential implications of the gut-brain connection for the treatment of various mental illnesses Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee / Author Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/Chinese National Natural Research Foundation, Stanley Medical Research Institute Consultant/Advisor: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout. Support: This activity is supported solely by the provider, NEI. Released: April 13, 2020          CME credit expires: April 13, 2023

How do you manage billing and insurance for telepsychiatry? What are some challenges to treating patients who may not be tech saavy? In part 2 of this episode, we address these questions and more, providing you with the most current information on the practical implications of telepsychiatry in our interview with psychiatric nurse practitioner, Michele Novella.  Michele Novella, PMHNP-BC, PMHCNS-BC, is the owner and medical director of Star Psychiatric Healthcare, LLC, in Danbury, CT. She was educated at Fairfield University in Fairfield, CT, and received her Master's Degree in Adult Psychiatric Nursing from Yale University, graduating with high Honors. Additionally, Ms. Novella is an inductee into the Sigma Theta Tau International Honor Society and is an active member of the ANA, APNA, and CTAPRNS. She is also a past recipient of the American Cancer Society's prestigious "Excellence in Onocology" Nursing Award for the State of CT.  She is a national speaker for several pharmaceutical companies, including Takeda and Lundbeck. Additional Resources:  Telepsychiatry Applications/Programs: Kareo: https://www.kareo.com/ Doxy.Me: https://doxy.me/ Zoom: https://zoom.us/ ICD-10-CM Official Coding Guidelines from the CDC: https://www.cdc.gov/nchs/data/icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf 

In this episode, we discuss the importance and practical implications of telepsychiatry in the field of mental health, with psychiatric nurse practioner, Michele Novella. Has your practice been impacted by the COVID-19 pandemic? In part 1 of this episode, Michele takes you step-by-step through the process of implementing telepsychiatry into your practice. Learn about the "do's" and "don'ts", and important information that you will need to know to better treat your patients during this challenging time!  Michele Novella, PMHNP-BC, PMHCNS-BC, is the owner and medical director of Star Psychiatric Healthcare, LLC, in Danbury, CT. She was educated at Fairfield University in Fairfield, CT, and received her Master's Degree in Adult Psychiatric Nursing from Yale University, graduating with high Honors. Additionally, Ms. Novella is an inductee into the Sigma Theta Tau International Honor Society and is an active member of the ANA, APNA, and CTAPRNS. She is also a past recipient of the American Cancer Society's prestigious "Excellence in Onocology" Nursing Award for the State of CT.  She is a national speaker for several pharmaceutical companies, including Takeda and Lundbeck. Additional Resources:  Telepsychiatry Applications/Programs: Kareo: https://www.kareo.com/ Doxy.Me: https://doxy.me/ Zoom: https://zoom.us/ ICD-10-CM Official Coding Guidelines from the CDC: https://www.cdc.gov/nchs/data/icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf 

In this episode, we raise awareness about a forgotten, yet extremely vulnerable population at high risk for traumatic brain injury (TBI). What are ways that we can better screen for patients who have experienced intimate partner violence (IPV)? How are types of brain injuries unique in this population? Are there neuroimaging techniques that can more accurately detect IPV-related TBIs?  Deb York is a board certified Psychiatric-Mental Health Nurse Practitioner practicing in Colorado Springs, CO.  She completed her research certification as a Certified Clinical Research Associate at the Association of Clinical Research Professionals. Deb has a clinical focus in endocrine psychiatry for the treatment of a variety of psychiatric illnesses with specialized expertise in treatments for mood disorders involving menopause, andropause, PMS, PMDD and post-partum depression.  Her research focuses on conducting clinical trials to identify and evaluate novel psychopharmacological and neuroradiological interventions for traumatic brain injury, mood disorders, and pediatric psychiatric illnesses. Additionally, Deb is certified in Bioidentical Hormone Replacement Therapy through the Academy for Preventive and Innovative Medicine by WorldLink Medical. Deb has over 25 years in the clinical trials industry conducting clinical research in pharmaceuticals & biologics, with a specialty in Women’s Health, CNS & psychiatric clinical trials. Deb completed her Bachelor of Science in Nursing at the University of Missouri-St. Louis Barnes College of Nursing-Washington University.  She completed her Master’s Degree at the University of Cincinnati in Nurse Midwifery and her Post-Master’s Certification from the University of Cincinnati in Psychiatry-Mental Health. Additionally, Deb is an Adjunct Professor at the College of Nursing at the University of Cincinnati and Director of Clinical Research at Mountain Mind.  

What are ketones and how are they related to mental health? What is the relationship between mitochondrial dysfunction and the ketogenic diet? What is the carnivore diet? If these are some of your questions when it comes to nutrition and mental health, you won't want to miss Part II of this exciting interview with Dr. William Sauve'!

Are carbohydrates bad for me? Is the ketogenic diet good for the brain? What is the carnivore diet? These are questions that concern many people today, especially if you're interested in nutrition and the brain. In Part I of this episode we dive into this hot topic with Dr. William Sauve', where we discuss many of these questions and more!   Dr. William M. Sauve' is a psychiatrist in Virginia. He received his medical degree from Uniformed Services University of the Health Sciences and has been in practice between 11-20 years.

In Part II of this interview with Dr. Rona Hu, we discuss the most effective ways of assessing and preventing violence in the healthcare setting. Learn how to protect yourself, how to cope with such experiences, and how to support one another in the aftermath. 

In this episode, we dive into a topic that is not talked about enough, yet many clinicians experience assault by patients. Here, we address how to identify risks, how to decrease escalation from agitation to aggression, and how to cope after a violent event has occurred with a patient. Dr. Rona Hu is the Associate Dean of Academic Affairs at Stanford University School of Medicine. She is a Clinical Professor at Stanford University, and she was the formal Medical Director of the Acute Psychiatric Unit at Stanford for 20 years.

In Part II of this episode, we continue to take a look back at 2019 with Dr. Andrew Cutler, as we reflect on the most FDA approvals, exciting research findings and all the important updates in psychopharmacology that could impact your practice.  Dr. Andrew Cutler is Chief Medical Officer (CMO) at the Neuroscience Education Institute (NEI). He has deeply rooted knowledge in clinical practice, academic experience, and emerging science in psychiatry through clinical trials. He is Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida. He has been the principal investigator on more than 400 psychiatric and medical clinical trials.

In this episode, we take a look back at 2019 with Dr. Andrew Cutler, as we reflect on the most FDA approvals, exciting research findings and all the important updates in psychopharmacology that could impact your practice.  Dr. Andrew Cutler is Chief Medical Officer (CMO) at the Neuroscience Education Institute (NEI). He has deeply rooted knowledge in clinical practice, academic experience, and emerging science in psychiatry through clinical trials. He is Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida. He has been the principal investigator on more than 400 psychiatric and medical clinical trials. Stay tuned for more exciting reflections from 2019, in Part II of this episode. 

Join Dr. Andy Cutler through this lightning-speed review of how to manage antipsychotic medications and treat psychosis. Tune in for the latest information from this year's Congress! 

In this episode, we interview Dr. Donna Wilcock, about her cutting-edge research on the role of inflammation, vascular impairment, and cerebrovascular disease on Alzheimer's disease! Dr. Donna Wilcock is a Professor of Physiology at the University of Kentucky and the Sanders-Brown Center on Aging.

In this fascinating extended Q&A session with Dr. Rona Hu, join us as she answers important questions about her presentation on the assessment and management of agitation!

Join us for this exciting extended Q&A session with Dr. Kari Franson, as she addresses your questions from her presentation on the legislation and legalization of marijuana and protecting your patients!

In this extended Q&A session with Dr. Andrew Cutler, we discuss your most important questions from his presentation on antipsychotic treatment approaches beyond the D2 receptor!

Join us for a fascinating extended Q&A with Dr. Leslie Citrome, where he answers your most pressing questions from his presentation on the assessment and treatment of eating disorders!

In this exciting extended Q&A session, Dr. William Sauve’ addresses some of your unanswered questions about his presentation on the current applications for the treatment of neuropsychiatric conditions with brain stimulation techniques!

In this episode, listen in for an extended Q&A session with Dr. Roger McIntyre as he answers some fascinating questions about his presentation on inflammation and depression: the gut-brain interaction!

Join us for this exciting extended Q&A session where Dr. Timothy Wilens addresses your most pressing questions from his presentation on transitioning from adolescence to adulthood with ADHD!

In this episode, we discuss the publishing process from the perspective of the Managing Editor of CNS Spectrums, Lisa Arrington. Learn how to avoid the most common mistakes in the submission process, and how to let your submission stand out! Lisa Arrington is Managing Editor for CNS Spectrums at Cambridge University Press. Check out the scientific poster session for CNS Abstracts at this year’s NEI Congress 2019. Saturday evening, November 9th!

Did you know that 20% of hospitalizations for adverse drug events are caused by drug interactions? In this episode, we talk to Dr. Patrick Finley, an expert in drug interactions and pharmacokinetics. Learn about the major factors that affect or alter the pharmacokinetic stages of drug metabolism. Explore more about cytochrome P450s and why they’re important when it comes to prescribing. Learn what drugs inhibit or induce these enzymes, and what the current research is on how to adjust drug dosage, according to genetic testing. Do you want to be able to fine-tune your approach to prescribing medications, to develop more individualized treatment approaches for your patients? Then you won’t want to miss this episode! Dr. Patrick Finley is a Professor of Clinical Pharmacy at the University of California, San Francisco. He is also a board-certified psychiatric pharmacist and has been a licensed medical provider for the last 15 years.  Resources:  Comprehensive Cytochrome P450 table with References: www.medicine.iupui.edu/flockhart/    QTc prolongation: www.crediblemeds.org  EBM review of herbs and supplements: www.naturalstandard.com  International Pharmacogenetics Consortium: www.pharmgkb.org/   

In this episode, we go behind the scenes of this year’s annual American Psychiatric Nurses Association (APNA) meeting and interview Dr. Mary Moller on a presentation she will be jointly delivering with Dr. Kate Wheeler, titled “A Third Nervous System? Lions and Tigers and Bears, Oh My!” We discuss how to incorporate the polyvagal theory of trauma into practice and how to effectively treat patients who have experienced trauma. Learn how a better understanding of the way the mammalian nervous system has evolved, may empower patients to transition from a more primitive freezing response, to becoming more active and socially engaged, thus resulting in enhanced healing. Dr. Mary D. Moller, DNP, ARNP, PMHCNS-BC, CPRP, FAAN is an advanced registered nurse practitioner who is dually certified as a clinical specialist in adult psychiatric-mental health nursing and a psychiatric rehabilitation practitioner. She is an Associate Professor at Pacific Lutheran University in Tacoma, WA where she is Lead Faculty for the Undergraduate Psychiatric Nursing Program and coordinator for the development of a Doctor of Nursing Practice program for psychiatric-mental health nursing. She is also the Director of Psychiatric Services for Northwest Center for Integrated Health in Tacoma, WA where she is in practice as a psychiatric ARNP treating patients in a triple integration agency: substance abuse, mental illness, and primary care. Resources: Book by Stephen W. Porges: “Clinical Applications of the Polyvagal Theory: The Emergence of Polyvagal Therapies”: https://www.amazon.com/Clinical-Applications-Polyvagal-Theory-Polyvagal-Informed/dp/1324000503/ref=sr_1_5?keywords=Stephen+Porges&qid=1570048266&sr=8-5  “The Pocket Guide to the Polyvagal Theory: The Transformative Power of Feeling Safe”: https://www.amazon.com/Pocket-Guide-Polyvagal-Theory-Transformative/dp/0393707873/ref=sr_1_3?keywords=Stephen+Porges&qid=1570048328&sr=8-3 Application of polyvagal theory in therapy: “The Polyvagal Theory in Therapy” by Deb Dana: https://www.amazon.com/Polyvagal-Theory-Therapy-Interpersonal-Neurobiology/dp/0393712370/ref=sr_1_1_sspa?keywords=Stephen+Porges&qid=1570048328&sr=8-1-spons&psc=1&spLa=ZW5jcnlwdGVkUXVhbGlmaWVyPUEzVlhPQUM4SkpSUDBCJmVuY3J5cHRlZElkPUEwMTc4MTU2MVBWUDJIWUNCSFNTMyZlbmNyeXB0ZWRBZElkPUEwODk5Nzk2MVVFR1FNVDJUM0tUUiZ3aWRnZXROYW1lPXNwX2F0ZiZhY3Rpb249Y2xpY2tSZWRpcmVjdCZkb05vdExvZ0NsaWNrPXRydWU=  Books by Joseph LeDoux: “Anxious” https://www.amazon.com/Anxious-Using-Brain-Understand-Anxiety/dp/0143109049/ref=sr_1_2?keywords=joseph+ledoux&qid=1570048552&sr=8-2 

Adult Deficit Hyperactivity Disorder (ADHD) is a life-long disorder that may not be diagnosed until much later in life. Symptoms of distraction, forgetfulness, and procrastination become confused with normal aging, yet may cause a significant disturbance to the quality of life in these patients. In this episode, we interview Dr. David Goodman, an expert on adult ADHD about how to effectively manage ADHD in the older population. We discuss hidden challenges, and the most effective approach for accurate diagnosis. Dr. Goodman is an assistant professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD.  Resources: David W. Goodman, M.D., LFAPA, http://www.addadult.com National Public Radio interview with Dr. David Goodman on Older Adults with ADHD, https://www.npr.org/sections/health-shots/2016/01/18/462978127/cant-focus-it-might-be-undiagnosed-adult-adhd Psychiatric Times podcast with Dr. David Goodman on Older Adults with ADHD, https://www.psychiatrictimes.com/adhd/adhd-older-adults

Should you tell a patient if they are diagnosed with Alzheimer’s disease? In this exciting debate listen as Dr. McIntyre and Dr. Citrome weigh in on the pros and cons!

In this episode we discuss Suicide Awareness Prevention Month with forensic psychiatrist, Dr. Ryan Wagoner! Did you know that more first responders take their own life than die in the line of duty? Dr. Wagoner shares with us what it’s like being a forensic psychiatrist, how first responders struggle with trauma, and the stigma associated with Post Traumatic Stress Disorder in first responders. Dr. Wagoner is an Assistant Professor in the Department of Psychiatry and Behavioral Neurosciences at the University of South Florida. He is board certified as a forensic psychiatrist, and leads the Forensics division at the University of South Florida. He is also the program director of the Forensics Psychiatry Fellowship.

In this exciting debate from this year's NEI Synapse, Dr. Stephen Stahl and Dr. Roger McIntyre discuss whether the DSM-5 accurately captures criteria for different psychiatric disorders, such as Depression with Mixed Features. Who will win this one?

In this fascinating episode, we explore the status of mental health diversion today. Dr. Katherine Warburton explains how the diversion process works and many of the sensitive issues that need attention. She also shares some of the most current scientific research on this topic today. Dr. Warburton is an associate clinical professor of psychiatry at UC Davis. She is also Medical Director at the California Department State Hospitals.

Join us for Part II of this exciting interview with Dr. Napoleon Higgins Jr! Dr. Napoleon B. Higgins, Jr. is a psychiatrist in the Houston/Clear Lake City Area. He is also CEO and President of Bay Pointe Behavioral Health Service, Inc., and South East Houston Research Group, Inc. He also practices as the Medical Director of Hold My Hand Residential Treatment Center. Dr. Higgins has worked with and founded many programs that help to direct inner city young men and women to aspire to go to college and finish their educational goals. He has worked with countless community mentoring programs and has special interest in trauma, racism, and inner city issues and how they affect minority and disadvantaged children. His books can be found at Amazon:  "Mind Matters: A Resource Guide to Psychiatry for Black Communities”: (https://www.amazon.com/dp/1979510687/ref=cm_sw_em_r_mt_dp_U_ZBahDb46SRHSH),  “How Amari Learned to Love School Again”: (https://www.amazon.com/dp/0997260564/ref=cm_sw_em_r_mt_dp_U_kDahDbTNM7KJJ) "Transition to Practice: 21 Things Every Doctor Must Know in Contract Negotiations and the Job Search" (kindle or paperback direct from Amazon)

Dr. Napoleon B. Higgins, Jr. is a psychiatrist in the Houston/Clear Lake City Area. He is also CEO and President of Bay Pointe Behavioral Health Service, Inc., and South East Houston Research Group, Inc. He also practices as the Medical Director of Hold My Hand Residential Treatment Center. Dr. Higgins has worked with and founded many programs that help to direct inner city young men and women to aspire to go to college and finish their educational goals. He has worked with countless community mentoring programs and has special interest in trauma, racism, and inner city issues and how they affect minority and disadvantaged children. His books can be found at Amazon:  "Mind Matters: A Resource Guide to Psychiatry for Black Communities”: (https://www.amazon.com/dp/1979510687/ref=cm_sw_em_r_mt_dp_U_ZBahDb46SRHSH),  “How Amari Learned to Love School Again”: (https://www.amazon.com/dp/0997260564/ref=cm_sw_em_r_mt_dp_U_kDahDbTNM7KJJ) "Transition to Practice: 21 Things Every Doctor Must Know in Contract Negotiations and the Job Search" (kindle or paperback direct from Amazon)

June is Postraumatic Stress Disorder (PTSD) Awareness Month! In this episode we interview Dr. John Liebert, an expert in military-related and civilian PTSD.  Dr. Liebert is a psychiatrist in Scottsdale, Arizona. He received his medical degree from McGill University Faculty of Medicine and has been in practice for more than 20 years. His special interests include complex mood, impulse and anxiety disorders for both adult, child, and geriatric populations.  Dr Liebert is a graduate of The US Air Force School of Aerospace Medicine and served as a Flight Surgeon in charge of Human Reliability Program for transportation of nuclear warheads worldwide.   His book “Wounded Minds: Understanding and Solving the Growing Menace of Post-Traumatic Stress Disorder” can be found here: https://www.amazon.com/Wounded-Minds-Understanding-Post-Traumatic-Disorder/dp/1634502876  His textbook: Psychiatric Criminology, which has a section on special problems of veterans in Chapter 9 can be found here: https://www.amazon.com/Psychiatric-Criminology-Roadmap-Rapid-Assessment/dp/149871417X 

Join us in this exciting debate about when side effects warrant medication change. Dr. Andrew Cutler and Dr. Roger McIntyre address some of the most important issues surrounding this topic. This podcast was recorded live at NEI's 2019 Synapse Conference in Asheville, North Carolina! 

May is Borderline Personality Disorder Awareness Month! Join us in this fascinating interview with Dr. Robert Gregory. Dr. Robert Gregory is Professor of Psychiatry and Behavioral Sciences at Upstate Medical University where he serves as Director of the Psychiatry High Risk Program, a treatment program for youth and young adults struggling with suicidal thoughts or behaviors.  Areas of interest and special expertise include borderline personality disorder, addictions, and suicide prevention.  He is the developer of one of the evidence-based treatments for borderline personality disorder, called Dynamic Deconstructive Psychotherapy.

How can you tell the difference between postpartum blues and postpartum depression? Join us in this episode, as Dr. Marlene Freeman addresses questions like this about maternal mental health.  Dr. Marlene Freeman is the Associate Director of the Center for Women’s Mental Health at Massachusetts General Hospital and the Medical Director of the MGH Clinical Trials Network and Institute (CTNI).Her research and clinical expertise is in the areas of mood disorders and women’s mental health. She also has had clinical and research interests in the areas of nutrition, integrative medicine, and mental health. She previously directed programs in women’s mental health at the University of Arizona College of Medicine and at UT-Southwestern in Dallas.

Join us in this episode, as Dr. Mago answers some important questions on his presentation about side effects that can lead to nonadherence!

In this episode, Dr. McIntyre addresses some of your unanswered questions from his presentation on depression, dementia and cognition! 

Join us in this episode with Dr. Cutler as he addresses some fascinating questions about his presentation on the most current findings on how to recognize and manage tardive dyskinesia!

In this episode, Dr. Hu addresses important questions on her two presentations at Synapse. Join her, as she answers questions on postpartum depression and psychosis. Next, she addresses the most pressing questions on suicide risk and prevention. 

In this episode, join Dr. Robb while see addresses some of your most pressing questions about her presentation at Synapse on pediatric mood disorders! 

You won't want to miss this episode! Chairman, Dr. Roger S. McIntyre highlights what's to come over the next few days. You'll hear about a change in our format, and some of the most exciting topics to date! Our team is in Asheville, NC putting final touches on the 2019 NEI Synapse experience! We're eager to welcome our attendees and share the tips, tools, and knowledge that we've been cultivating for the past year. 

April is Parkinson's Disease Awareness Month! Join us in this interview with Dr. Laxman Bahroo. We address novel therapeutics on the horizon, changes in the treatment for Parkinson's Disease, and how to effectively communicate with patients about the course of this disease to design appropriate individual treatment plans! Dr. Laxman Bahroo is currently an Associate Professor and Director of the Residency Program in the Department of Neurology at Georgetown University. He is Movement Disorders specialist and manages a busy clinic with interests in medical and surgical treatment of Parkinson’s disease and Essential Tremor. He also specializes in the therapeutic role of botulinum toxin injections for dystonia and spasticity. Dr. Bahroo has lectured at regional and national conferences. He has presented at grand rounds at regional hospitals about pertinent topics in Movement Disorders and Neurology. Dr Bahroo actively participates in research trials focusing on emerging movement disorders therapies.

April is Autism Awareness Month! Join us, as we interview Dr. Arshya Vahabzadeh on the hallmark features of autism, and how to use digital technological advancements to effectively treat symptoms related to autism.  Dr. Vahabzadeh is a family physician, having completed training under the Royal College of General Practitioners. Dr. Vahabzadeh is deeply interested in neurodevelopmental disorders, including autism and schizophrenia. He is also a leadership fellow of the American Psychiatric Association. He practices as a resident child and adolescent psychiatrist at Massachusetts General Hospital and McLean Hospital, in addition to being a clinical fellow at Harvard Medical School. His research experience has encompassed several lines of study, including genetics, novel psychopharmacology and social cognition. He is also Chief Medical Officer at Brain Power, a neurotechnology company with a wearable smart glass system for patients with autism. Dr. Vahabzadeh is also a strong proponent of mental health education, and has written editorials for Psychology Today, The Huffington Post, APA Healthy Minds, Boston Magazine and CNN.

In this episode, we discuss depression-related cognitive impairment with Dr. Roger McIntyre. Learn about the difference between hot and cold cognition, along with how to identify depression-associated cognitive symptoms that could alter the effectiveness of the very treatment approaches used for depression. Learn more about the relationship between bouts of depression and cognitive impairment and how to address this in your practice. Dr. Roger McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director for the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre was named by Clarivate Analytics/Thomson Reuters in 2014, 2015, 2016, 2017 and 2018 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.

March is Brain Injury Awareness Month! In this episode we interview Dr. William Sauvé about the most novel neuroscience research on the diagnosis, management, and treatment for traumatic brain injury.  Dr. William Sauvé commenced his career in psychiatry with the U.S. Marines followed by service as a Division Officer of inpatient psychiatry at the Naval Medical Center of San Diego.  After his years of military practice, Dr. Sauvé relocated to Richmond, Virginia where he started a private psychiatric practice. He joined Greenbrook TMS NeuroHealth Centers as Regional Medical Director of the Rockville, Richmond and Charlottesville locations in January 2014. 

In this episode we discuss how to manage the opioid crisis when it comes to patient care, from effective communication with patients, to the most novel treatments with Dr. Thomas Kosten.  Dr. Kosten is the JH Waggoner Chair and Professor of Psychiatry, Pharmacology, Immunology and Neuroscience, Vice Chair for Psychiatry and Co-director of the Dan L. Duncan Institute for Clinical and Translational Research (ICTR) at Baylor College of Medicine. His pharmacotherapy research activities include a cocaine vaccine, disulfiram for cocaine dependence, vasodilators for cocaine-induced cerebral perfusion defects and buprenorphine for opioid dependence. In addition to these pharmacotherapies, he has advanced the understanding of opiate and cocaine dependence mechanisms and treatment using SPECT and functional MRI neuroimaging.

February is Eating Disorder Awareness Month! Binge Eating Disorder (BED) is the most common eating disorder, and yet it is one of the most underdiagnosed. In this episode, we interview Dr. Leslie Citrome, an expert in BED about the challenges that prevent accurate diagnosis, and what to do to overcome these. Learn how to communicate effectively with your patients so that this disorder does not go overlooked. Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. His primary research interests have centered on psychopharmacologic approaches to schizophrenia, bipolar disorder, major depressive disorder, the management of treatment-refractory schizophrenia, and the management of aggressive and violent behavior. Dr Citrome has authored or coauthored more than 400 research reports, reviews, chapters, and abstracts in the scientific literature.

  As we continue our stimulating discussion of Mental Wellness Month, we interview Dr. Gary Small on how to maintain brain health as we age!  Dr. Gary Small is a Longevity Lifestyle Geriatric psychiatrist and director of the UCLA Longevity Center. He is also a professor in Psychiatry and Behavioral Sciences. Dr. Small has been named one of the world’s leading innovators in science and technology by Scientific American magazine, and his research, supported by the National Institutes of Health, has made headlines in TheWall Street Journal, The New York Times, and USA Today. He is known for his ability to both entertain and teach.  Dr. Small has published several books on how to maintain brain health as we age and how to stay committed to mental wellness. You can find his books here at: http://drgarysmall.com/books/

January is Mental Wellness Month. Join us for Part II of our interview with Dr. Dan Diamond. He is a leader in protecting mental health in the face of catastrophe and teaching people how to perform exceptionally under pressure. In this episode, we address his “trench-tested” techniques to help you combat burn-out and to help you thrive in the midst of stress that you face as a medical provider.  Dr. Dan Diamond is a uniquely qualified leader with over 30 years of international disaster experience. He founded and serves as the Director of the Nation’s first state-affiliated medical disaster response team and he has responded to a variety of international disasters. Most recently he responded to the typhoon in the Philippines and he served as the Medical Director for Medical Teams International’s First Response Team to Haiti. Following Hurricane Katrina, he played a strategic role as Director of the Mass Casualty Triage Unit at the New Orleans Convention Center. Dr. Diamond is a Clinical Assistant Professor at the University of Washington School of Medicine. He is a part-time practicing physician at Multicare Immediate Clinic. He was a member of the Editorial Board for the Primary Care Companion to the Journal of Clinical Psychiatry. Dr. Diamond provides coaching programs that offer cutting edge strategies to help you thrive under pressure and under extreme circumstances. He also has a podcast, “Trench-Tested Leadership Podcast”, which you can find in iTunes. You can access all of his resources at: www.dandiamondmd.com. His book, “Beyond Resilience: Trench-Tested Tools to Thrive Under Pressure” can be found at Barnes & Noble.

January is Mental Wellness Month. Dr. Dan Diamond is a leader in protecting mental health in the face of catastrophe and teaching people how to perform exceptionally under pressure. In this episode, we address his “trench-tested” techniques to help you combat burn-out and to help you thrive in the midst of stress that you face as a medical provider. Dr. Dan Diamond is a uniquely qualified leader with over 30 years of international disaster experience. He founded and serves as the Director of the Nation’s first state-affiliated medical disaster response team and he has responded to a variety of international disasters. Most recently he responded to the typhoon in the Philippines and he served as the Medical Director for Medical Teams International’s First Response Team to Haiti. Following Hurricane Katrina, he played a strategic role as Director of the Mass Casualty Triage Unit at the New Orleans Convention Center. Dr. Diamond is a Clinical Assistant Professor at the University of Washington School of Medicine. He is a part-time practicing physician at Multicare Immediate Clinic. He was a member of the Editorial Board for the Primary Care Companion to the Journal of Clinical Psychiatry. In 2010, the American Red Cross gave him the “Real Hero” award and he also received the Washington State Governor’s Award of Excellence for his work in Haiti. In 2014, Dr. Diamond received the President's Volunteer Service Award from President Obama and he also received the Quality of Care Lifetime Achievement Award, Healthcare Heroes. Dr. Diamond provides coaching programs that offer cutting edge strategies to help you thrive under pressure and under extreme circumstances. He also has a podcast, “Trench-Tested Leadership Podcast”, which you can find in iTunes. You can access all of his resources at: www.dandiamondmd.com. His book, “Beyond Resilience: Trench-Tested Tools to Thrive Under Pressure” can be found at Barnes & Noble.  

The use of medicinal marijuana has been a controversial topic, and there is recently evidence of treatment for various mental health disorders. In this episode, Dr. William Sauvé discusses the pros and cons of marijuana within the medical setting. Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines. After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well. He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.

In this episode we interview Dr. Rona Hu on how to manage aggression and agitation in patients. Agitation and aggression in patients is a serious and potentially dangerous consequence of psychiatric illness. In this episode, we explore the most current, effective non-pharmacological and pharmacological treatments available for the management of aggression and agitation.    Dr. Hu is Medical Director of the Acute Psychiatric Inpatient Unit at Stanford Hospital, specializing in the care of those with serious mental illnesses, including schizophrenia, bipolar and depression. She completed medical school and residency in psychiatry at the University of California, San Francisco, and fellowships in Pharmacology and Schizophrenia Research through the National Institutes of Health. She is also active in the minority issues and cultural psychiatry, and has received regional and national recognition for her clinical care, research and teaching. Disclaimer: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Send feedback on Facebook or LinkedIn. Rate us on iTunes!

In this episode we share Dr. Roger McIntyre's perspective on central themes that underlie mental health conditions, which he shared with us this past year at Synapse in Las Vegas. Find out what homeostasis and hedonism might mean for you in terms of treating patients!  Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.

Suicide is a topic that many mental health providers and clinicians find particularly challenging in their practice. This month is National Suicide Prevention Awareness Month. Join us, as we interview the Chief Medical Officer for the American Foundation for Suicide Prevention (AFSP), Dr. Christine Moutier. Dr. Moutier knows the impact of suicide firsthand. After losing colleagues to suicide, she dedicated herself to fighting this leading cause of death.Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide. She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets. For more information on the AFSP please visit: asfp.org

In Part II of this interview with Dr. Rona Hu, we discuss building awareness about mental health issues for minorities and the challenges that come with treating this vulnerable population. Learn strategies about communication with patients from various cultures, and increase your awareness of multi-cultural attitudes that impact mental health in your practice. Dr. Rona Hu is a Clinical Associate Professor at the Department of Psychiatry and Behavioral Sciences and Medical Director of the Acute Psychiatric Inpatient Unit at Stanford University School of Medicine. She is also active in the minority issues and cultural psychiatry, and has received regional and national recognition for her clinical care, research and teaching.

In Part I of this interview with Dr. Rona Hu, we discuss building awareness about mental health issues for minorities and the challenges that come with treating this vulnerable population. Learn strategies about communication with patients from various cultures, and increase your awareness of multi-cultural attitudes that impact mental health in your practice. Dr. Rona Hu is a Clinical Associate Professor at the Department of Psychiatry and Behavioral Sciences and Medical Director of the Acute Psychiatric Inpatient Unit at Stanford University School of Medicine. She is also active in the minority issues and cultural psychiatry, and has received regional and national recognition for her clinical care, research and teaching.

In this episode, Dr. Mary Moller addresses questions about a wellness approach to treating Post-Traumatic Stress Disorder (PTSD).  Dr. Mary D. Moller is an internationally known psychiatric mental health nurse clinician, researcher, educator, and presenter. She is an advanced registered nurse practitioner who is dually certified as a clinical specialist in adult psychiatric-mental health nursing and a psychiatric rehabilitation practitioner. She is an Associate Professor at Pacific Lutheran University in Tacoma, WA where she is coordinator of the psychiatric nurse practitioner Doctor of Nursing Practice program. She is also the Director of Psychiatric Services for Northwest Center for Integrated Health in Tacoma. For access to the Wellness Assessment Tool click HERE.

The normal aging process alters the adult brain in many different ways. Cognition tends to slow down, and there are cellular and structural changes. Lifestyle behaviors such as proper nutrition and exercise can slow the aging process and preserve brain health. In this episode, Dr. Stephen Stahl addresses questions about the most current scientific research on how healthy lifestyle behaviors influence the brain in positive ways.

In this exciting interview, Dr. Jonathan Meyer discusses what's on the horizon for the treatment of psychosis related to Parkinson's disease. Learn about how previous challenges may be overcome by novel therapeutic advances. 

In this engaging interview, Dr. Thomas Schwartz shares with you the most current and helpful information on how to manage treatment modifications for your patients with a special emphasis on antidepressants. Tune in to learn more! 

Learn what's on the horizon for the development of antidepressants. How are we moving beyond the traditional "monoamine approach"? In this exciting interview with Dr. Andrew Cutler we'll learn about some of the cutting edge research in this area!

In this episode, we interview Dr. Roger McIntyre about the newest findings on inflammation and depression. 

In this interview, Dr. Rajnish Mago discusses how to deal with the challenge of side effects when treating mental illness. 

In this episode, we interview Dr. William Sauvé on the basis behind transcranial magnetic stimulation (TMS)-- how it works, and how it can be used to treat much more than treatment resistant depression. Dr. Sauvé commenced his career in psychiatry with the U.S. Marines followed by service as a Division Officer of inpatient psychiatry at the Naval Medical Center of San Diego.  After his years of military practice, Dr. Sauvé relocated to Richmond, Virginia where he started a private psychiatric practice. He is the Medical Director of Greenbrook TMS Neurohealth Center. 

In this episode, army combat veteran, Justin Davis shares his unique experience about having multiple combat-induced TBIs, and his recovery through golf rehabilitation. Justin is paying it forward by opening his own Golf Rehabilitation center in California for veterans. Learn more about it in this episode!

In this engaging interview, we ask Dr. Nora Volkow what common misconceptions exist that can influence the way clinicians treat pain and manage opioid addiction. We also ask her what risk factors are associated with opioid addiction and what early warning signs exist that a patient is becoming addicted. She also shares with us the most effective pain biomarkers available today, and in development so that we may be able to more effectively manage pain and avoid some of the risk associated with opioid treatment for pain. 

In this interview, we ask the Medical Director of California Department State Hospitals, Dr. Katherine Warburton the latest update on inpatient violence. We discuss different classifications of violence, risk factors associated with violence, and the most recent significant reduction in violent acts since a panel of experts along with NEI published guidelines on how to effectively manage and treat violence. 

In this exciting interview we ask Dr. Vahabzadeh about his role as chief medical officer at Brain Power and the exciting projects that they are developing to help patients with autism. We also discuss the use of digital information, apps, and devices to help accurately predict suicide risk. We conclude with a sneak peak of what lies on the horizon for mental health in the digital age! 

A podcast by the Neuroscience Education Institute. Stop by booth 645 at the American Psychiatric Association conference in San Diego. We'll also be interviewing some of the top psychiatrists in their fields so tune in here! 

The Neuroscience Education Institute (NEI) is committed to help raise the standard of mental health by providing imaginative medical education that focuses on the highest level of learning. Each episode offers an opportunity to learn about current issues in psychiatry from key opinion leaders in the medical field. NEI's Sages of Psychopharmacology Podcast would be of value to anyone with an interest in neuropsychiatric diseases and psychopharmacology.